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The number of three-dimensional structures of potential protein targets
available in several platforms such as the Protein Data Bank is subjected to a
constant increase over the last decades. This observation should be an additional
motivation to use structure-based methodologies in drug discovery. In the recent
years, different success stories of Structure Based Drug Design approach have
been reported. However, it has also been shown that a lack of druggability is
one of the major causes of failure in the development of a new compound.The
concept of druggability can be used to describe proteins with the capability to
bind drug-like compounds. A general consensus suggests that around 10% of
the human genome codes for molecular targets that can be considered as druggable.
Over the years, the protein druggability was studied with a particular
interest to capture structural descriptors in order to develop computational
methodologies for druggability assessment. Different computational methods
have been published to detect and evaluate potential binding sites at protein
surfaces. The majority of methods currently available are designed to assess
druggability of a static structure. However it is well known that sometimes a few
local rearrangements around the binding site can profoundly influence the affinity
of a small molecule to its target. The use of techniques such as molecular dynam-
ics (MD) or Metadynamics could be an interesting way to simulate those variations.
The goal of this thesis was to design a new computational approach, called
JEDI, for druggability assessment using a combination of empirical descriptors
that can be collected ‘on-the-fly’ during MD simulations. JEDI is a grid-based
approach able to perform the druggability assessment of a binding site in only a
few seconds making it one of the fastest methodologies in the field. Agreement
between computed and experimental druggability estimates is comparable to
literature alternatives. In addition, the estimator is less sensitive than existing
methodologies to small structural rearrangements and gives consistent druggability
predictions for similar structures of the same protein. Since the JEDI function is
continuous and differentiable, the druggability potential can be used as collective
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variable to rapidly detect cryptic druggable binding sites in proteins with a variety
of MD free energy methods.
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Introduction
The first chapter introduces the motivation, the theoretical, experimental and
computational concepts used throughout the thesis in the context of target-based
drug discovery.
2 1. Introduction
In the past, the drug discovery process was mainly based on screening of
natural products based on the success of traditional medicines and herbal reme-
dies.1 Over the last 30 years, only one third of new drugs approved annually by
the Food and Drug Administration came from natural products with sometimes
semi-synthetic modifications.2, 3 Therefore, the discovery of new structures derived
from natural products that have not been already registered, is becoming more
difficult, encouraging the pharmaceutical industry to develop innovative strate-
gies.4–6 Progress achieved in the field of chemical synthesis and pharmacology
have led to a systematic approach to develop rapidly new drug candidates with a
greater efficiency.7 During the successive phases of the modern drug discovery
process, thousands of molecules are screened and tested for desirable properties in
preclinical models of diseases, leading to a very small number of drug candidates
tested in clinical trials (Figure 1.1). The elapsed time between the identification
of a relevant biological target and the marketing of a new drug is about 14 years
with total research and development costs superior to $ 800 million.7–9
Therapeutic targets are usually single proteins or complexes involved in
disease. A rough estimation suggests that all the commercialized drugs to date
target between 300 and 500 different proteins.10–12 However, these protein drug
targets are not equally distributed among the proteome.13 Certain families of
proteins are more represented in the human genome, or more frequently involved
in pathological pathways. However it may be difficult to identify a drug that
target a protein without undesirable side-effects if there exist a large number of
homologous proteins. In addition, some proteins are simply easier to target than
others. For instance, it is easier for a pharmaceutical compound to perturb the
interactions between a small molecule and a protein binding site than to disrupt
protein-protein interactions.14, 15 In the past, the identification of a therapeutic





















































Figure 1.1: Target-based drug discovery process. This process takes place over a
period of 12-15 years and represents an investment around $ 800 million. The approval
of a new medication is usually the result of different experimental procedures that
involve the testing of thousands of compounds. Based on several criteria such as the
affinity and the selectivity for a protein target but also the toxicity and the efficiency,
the initial set of small molecules is then drastically refined and carefully optimized.
Only a few drug candidates are finally selected for further clinical trials.
HTS: High-Throughput Screening, SBDD: Structure-Based Drug Design, ADMET:
Absorption Distribution Metabolism Elimination Toxicology.
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in the fields of genomics, proteomics and bioinformatics, it is now possible to
identify more specifically genes and proteins that are involved in diseases but also
the more likely to become a therapeutic target.17, 18
Once a protein target has been selected, the next step of the target-based
process consists in identifying diverse small molecules able to bind the protein
of interest. These molecules are usually discovered using screening techniques
such as High-Throughput Screening (HTS) of large libraries containing up to
hundred thousands of compounds. However, because such approaches are usually
time consuming and expensive, knowledge-based methodologies are sometimes
preferred.15, 19 In recent years, virtual screening strategies, or screening in silico,
have been introduced as an alternative or complementary method to guide HTS.
These techniques are generally fairly easy to use and at a much lower cost than
experimental screenings.20 In addition, the constant evolution of technology
has dramatically reduced the computational cost required for the simulation of
complex systems or for the query of databases of several millions of molecules.
Virtual screening is now used in many projects to select, within large libraries of
molecules, a limited number of compounds that will be screened experimentally
accelerating the hit identification.21, 22 Then, a number of hits are carefully
selected for the lead generation and lead optimization phase. The choice of these
compounds is mainly based on the chemical structure and the affinity between
the ligand and its target. A good hit is usually a small molecule with an affinity
between 100 nM and 5 µM, a scaffold allowing to graft several substituents and
an overall chemical structure different from the pharmaceutical patents already
registered.23, 24 In the case of fragment-based drug design, a weaker binding
affinity may be observed.25 The hit-to-lead optimization step aims to increase the
affinity of a compound to its target to reach a dissociation constant in the order of
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the nM range. The lead optimization attempts to maintain sufficient specificity
towards other proteins. Additional parameters have to be taken into account
to finally propose few ‘drug-like’ molecules meeting the Absorption Distribution
Metabolism Elimination Toxicology (ADMETox) criteria.26–28 Owing to the
complexity of these steps, they are often considered as the most critical in drug
discovery.29 After this process, different phases of pre-clinical and clinical studies
are performed during which the safety and the efficacy of all drug candidates are
evaluated directly from trials in animals and patients respectively.30
1.1 Structure-based Drug Design
Recent advances in the field of structural biology bring a new dimension
to the characterization of therapeutic molecules. The Structure Based Drug
Design approach (SBDD) is an iterative process exploiting the physicochemical
properties extracted from a three dimensional (3D) protein structure, preferentially
interacting with a ligand, to design or optimize potential drug candidates (Figure
1.2).31
Accordingly, the structure determination of the protein target is a crucial
step in SBDD. Several approaches can be used. X-ray crystallography is cur-
rently the method of choice. Different orientations of a crystal containing a
continuous arrangement of a specific protein conformation are exposed to a X-ray
beam. Then, the protein structure is reconstructed from the diffraction pattern
obtained by the X-ray scattering caused by the molecules inside the crystal.32 The
























Figure 1.2: Structure-Based Drug Design approach. The SBDD approach aims to
optimize several hit molecules identified using diverse techniques such as HTS. During
this iterative process, the 3D structure of the protein target interacting with a ligand is
used to increase specific ligand parameters such as the affinity or the selectivity between
the two partners. At the end, the optimized ligands presenting the characteristics of
potential drug candidates are called leads.
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synchrotron radiation, has allowed solving the 3D structure of very large systems
such as the eukaryotic ribosome.33 In complement to crystallography, Nuclear
Magnetic Resonance (NMR) plays an increasing role in the structural analysis
of macromolecules in solution.34 NMR is a spectroscopic technique exploiting
the magnetic properties of atomic nuclei which absorb electromagnetic radiation
emitted at a specific frequency in the presence of a strong magnetic field. The
analysis of the observed frequency shift gives information about the environment
of the considered atom and allows the reconstruction of the structure step by step.
This technique does not require protein crystallization but is limited by other
constraints such as the size of the molecule being studied (only proteins with low
molecular weight) or its solubility. However, NMR offers the possibility to study
the dynamics of molecules, the interactions between macromolecules and solvent
and also structural changes that occur during the formation of transient complexes.
Furthermore, the technique opens up interesting possibilities, still little exploited,
for the study of macromolecules such as membrane proteins.35 Finally, compu-
tational approaches such as homology modelling may also be used for protein
structure determination.36 The resolution of the 3D structure of the protein target
is a crucial step for the success of SBDD approach. Indeed, structures based on
electron density maps at 1.2 Å resolution correspond to an atomistic resolution
allowing to characterize, without ambiguity, interactions between a ligand and
its target such as the presence of hydrogen bonding interactions. Structures
solved with a resolution higher than 3.0 Å are usually much less suitable for these
detailed analyses.5
Given a high-resolution structure, the protein is analysed to provide an
understanding of the binding mode between the ligand and its target. This
information is used to increase the affinity between the two partners by modifying
the chemical scaffold of the ligand or by introducing new substituents. The process
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is repeated until a series of lead molecules are obtained. A good lead molecule
will typically have an affinity in the nM range and a sufficient selectivity against
the target while respecting ADEMtox properties required for a drug candidate.
Historically, the first successes in the SBDD approach led to the development
of small molecules interacting with intracellular proteins such as protease inhibitors
of the AIDS virus (HIV), as well as molecules limiting the flu virulence factor.37, 38
Such examples have multiplied in the last ten years to include other types of
more complex molecules such as antibodies targeting extracellular or exogenous
proteins.39 This approach is also used to define the immunogenic domains of viral
proteins (shell of the virus) in order to develop new vaccines. This more rational
methodology is today an essential step to design more effective drug candidates
while also reducing both the timeline and the cost of the drug discovery process.
1.2 Druggability
The number of 3D structures of potential protein targets available in several
platforms such as the Protein Data Bank (PDB) is constantly increasing.40
This observation should be an additional motivation to use structure-based
methodologies in drug discovery. Over the last decades, around 60% of drug
discovery projects failed to identify viable leads able to modulate the activity of a
protein target due to a lack of druggability.4, 41, 42
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1.2.1 Definition
Druggability has been used in a large number of publications in different
fields to describe in different contexts the properties of genes, ligands or proteins.
Thus, the term is sometimes ambiguous.43 In this thesis, druggability is applied
to a protein target. Analyses of the sequenced human genome indicate that
less than 50% of disease-involved genes code for druggable proteins.44, 45 When
assessing protein druggability in target validation, one is often focused on the
capability of a therapeutic target to bind a drug-like small molecule, leaving aside
many important facets of the drug discovery and development process such as
selectivity.44 Therefore, protein druggability is closely related to the definition
of drug-likeness in this context. Historically, a drug-like compound is a molecule
meeting at least three of the criteria laid down by Lipinski’s Rule of Five:27, 46
• no more than 5 hydrogen bond donors.
• no more than 10 hydrogen bond acceptors.
• A molecular mass less than 500 daltons.
• An octanol-water partition coefficient (log P) not greater than 5.
Over the years, the characteristics of compounds presenting a good oral
bioavailability was refined, and other parameters such as the number of rotatable
bonds or aromatic rings were also found to play a significant role in the druglike-
ness.47, 48 However, those rules should not be considered as well established but
more as a guideline.49 The same shall apply to the definition of protein binding
site druggability. A druggable cavity tends usually to be a buried pocket, more
hydrophobic than hydrophilic and large enough to bind a small molecule able to
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modulate the protein activity. The definition of a nondruggable protein is also
questionable. Indeed, this term is not only applied to protein binding sites that do
not respect the druggability guidelines. The nondruggable target definition covers
also proteins binding a drug-like molecule with a high affinity but not able to
induce a therapeutic effect despite intensive efforts. In addition to druggable and
nondruggable proteins, a new category of druggable protein targets called ‘difficult’
has recently been introduced.50 It was suggested that this category of proteins
should be targeted with highly polar molecules administrated as pro-drugs. Since
druggability is closely linked to the notion of binding site in this specific context,
the terms ‘bindability’ or ‘ligandability’ have been recently introduced to avoid
ambiguities.51, 52 In the rest of this thesis, the term druggability is used to describe
the capability of protein target to bind a drug-like compound.
1.2.2 Existing Methodologies
With a growing interest in evaluating the capacity of a protein target to
bind a drug-like compound with a high affinity, several studies have focused
on developing computational methodologies that correlate structural descriptors
to this property. An early effort was contributed by Hajduk and coworkers.53
NMR-based fragment screening was used to develop a mathematical model for
druggability measurements using empirical descriptors correlated to NMR hit
rates. The methodology relies on the assumption that a druggable cavity tends
to bind more fragments than a nondruggable pocket. Based on the insight II
software to detect protein binding pockets, six structural descriptors (surface
area, polar & apolar contact area, the third & first principal component capturing
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the shape of the cavity and the pocket compactness) were found to correlate
with NMR hit rates. A second approach, called MAPPOD (Equation 1.1), was
published by Cheng et al. shortly after.50 The authors proposed a scoring function
to assess the maximal affinity between a small molecule and a binding site based







where γ(r) describes the curvature of the binding site, Atargetnonpolar & A
target
total captures
the apolar surface area and the total surface area respectively, Atargetdruglike is fixed
to 300 Å2 and C is a constant. The model was derived from the first publicly
available protein dataset compiled for the purpose of druggability studies. This
small dataset gathers 63 crystallographic structures of 27 different proteins that
have been subjected to past structure-based drug design campaigns. Protein
targets interacting with a commercialized drug were considered as druggable
whereas proteins without any drug on the market despite intensive efforts to
develop a medication are considered as non druggable. These approaches have
paved the way for the development of different computational methods that aim
to detect and evaluate potential binding sites at protein surfaces.
The public dataset compiled for MAPPOD was used to parameterize
Dscore (Equation 1.2), a druggability function coupled with the pocket detector
SiteMap.54, 55 Dscore is a simple linear combination of three descriptors reflecting
the volume, enclosure and hydrophobicity of the binding site.
Dscore = 0.094
√
n+ 0.6e− 0.324p (1.2)
where n is the number of site points, e is the degree of enclosure and p captures
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the hydrophobicity.
This approach was found to discriminate the three categories of protein targets
introduced by Cheng et al. One of the main limitations of Dscore is the execution
time. The method relies on expensive grid point energy calculations that may
significantly slow down the druggability predictions. Therefore, Dscore might not
be suitable for high throughput aplication.
To overcome this limitation, the fpocket has been developed.56, 57 This
methodology is able to assess protein druggability on very large dataset at a
reasonable computational cost, and is essantially based on hydrophobicity and
polarity predictions (Equation 1.3).
drugscore(z) = e
−z
1 + e−z (1.3)
where z is a linear combination of three descriptors: the normalized mean local
hydrophobic density, the pocket hydrophobicity score and the normalized polarity
score.
fpocket was trained and validated on a large dataset of 70 unique proteins publicly
available. In addition to distinguish druggable, difficult and nondruggable proteins,
the approach is one of the fastest in the field providing an interesting tool for
virtual screening. However, the pocket druggability predictions at the protein
surface are dependent on each other. Indeed, the mean local hydrophobic density
is normalized compared to other binding sites on the same protein. Consequently,
fpocket is not tailored to perform post-processing druggability assessment from
structures obtained using computational tools capturing protein flexibility in
solution such a molecular dynamics (MD) simulation.
More recently, MD-based methodologies have been introduced.58–60 One of
the first methods based on first-principles molecular simulations was published
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by Seco and coworkers.58 In this grid-based approach, an explicit restrained MD
simulation of a protein is performed in the presence of a given concentration of
isopropyl alcohol. The binding propensities of the probe at the protein surface
are then back-computed to evaluate a binding free energy (Equation 1.4).




where kB is the Boltzman constant, T is the temperature, Ni is the observed
population and N0 is the expected population.
A similar protocol was recently applied on different systems using several kinds of
probes without any restraints on the protein.59 The authors showed that probe
molecules could induce both local and global structural rearrangements increasing
the target druggability. However, all these techniques can generate a large number
of false positives or denature the protein at high probe concentrations, requiring
the judicious use of positional restraints to limit the occurrence of undesirable
conformational changes. Also, probe diffusion necessary to compute occupancies
to buried cavities can be very slow with standard MD approaches. To overcome
the limitations described previously, this thesis introduces a new grid-based
methodology, called JEDI (Just Exploring Druggability at protein Interfaces),
to assess protein druggability during a MD simulation. The entire process is
described in details in the chapters 4 & 5.
1.2.3 Protein Flexibility and Druggability
Protein binding site flexibility has been found to play an important role in the
binding process with a small molecule.61 This flexibility may involve small or
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large structural rearrangements. For instance, motions of few amino acids located
near the active site of acetylcholinesterase have been reported.62 Because of its
involvement in the memorization process and Alzheimer’s disease, this enzyme
has been extensively studied.63, 64 Using MD simulations, the authors were
able to identify two residues of the active site showing a high flexibility. Some
proteins show larger structural rearrangements to adopt an active form such as
streptococcal pyrogenic exotoxin B (SpeB). SpeB is a cysteine protease that is
secreted as an inactive zymogen (precursor protein of an enzyme).65 As with many
proteases, the activation of SpeB involves a proteolytic digestion that releases
a pro-domain to form the active enzyme. The displacement of the pro-domain
induces a large intramolecular rearrangement. A loop moves over 25 Å from
one pole to the opposite pole of the protein. A second loop, which contains the
catalytic histidine, is then free to move away from the substrate binding site. The
active conformation of the enzyme is formed and the protein may perform its
function. More recently, Alvarez-Garcia et al have studied the impact of protein
flexibility on binding free energy using MD simulations. Results suggest that an
accurate binding free energy prediction requires to consider binding flexibility.
Furthermore, they highlighted that the use of soft positional restraints may be an
interesting approach allowing to sample significant local structural rearrangement
at a reasonable computational cost.66
1.3 Classical Force Fields
The usefulness of a high-resolution 3D structure for a protein has been
discussed in the previous section. However, this set of cartesian coordinates






Figure 1.3: Illustation of the potential energy surface of a protein along a reaction
coordinate s.
represents only one structural conformation corresponding usually to a minimum
on the potential energy surface of the protein (Figure 1.2). It is well known that
in solution a protein may oscillate between structurally diverse conformations of
similar low energy. Nevertheless, it is often difficult to resolve with experiments
all these possible alternative structures. Techniques based on MD simulations
presented below represent an attractive tool to simulate those variations.
Simulations performed to explore the conformational space of a protein rely
on three criteria. First, the degrees of freedom that are explicitly simulated must
be defined. In this thesis, the degrees of freedom are the Cartesian coordinates
of the protein atoms. Then, it is necessary to define a mathematical function
to evaluate the total energy of the system for different arrangements of atoms.
In classical dynamics simulations, this function is called the Hamiltonian of the
system. The Hamiltonian is defined as the sum of the kinetic energy (Equation
1.5) and the potential energy (Equation 1.6).
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The kinetic energy of the system is only dependent on the mass m and the velocity








where vi is the velocity of atom i.
The calculation of the potential energy of a system relies on several parameters
such as the mass, the charge and the distance between atoms. Those variables and
the equations used to compute the potential energy are called a force field. Many
different force fields are available. However, all of them are based on experimental
data such as vibrational frequencies of bonds obtained by infrared spectroscopy or
by measuring the bond length using X-ray crystallography. Ab initio methods also
frequently provide crucial information on the twist angles or the bond vibration
frequencies.
In most of force fields used in biomolecular simulations, the potential energy
is described by the following equation:
V (r) = V (r)bonded + V (r)non−bonded + V (r)bias (1.6)
where the first term corresponds to the interactions between atoms with covalent
bonding including angles and dihedral angles, the second represents the van der
Waals and electrostatic interactions while the last term is used in specific cases
that will be described later.
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With knowledge of the forces acting on the particles in the system, it is possible
to solve equations of motions that predict the time evolution of the collection of
particles using Lagrangian or Hamiltonian formalisms. The Newton’s equations
of motion have been used in this thesis









where vi and fi are respectively the atomic velocity and the force acting on
the atom i at the time t. Newton’s equations are only valid for the Cartesian
coordinates ri of a particle with a mass mi. The initial particle velocities are













Numerical integration of the Equations 1.7, 1.9 and 1.10 are iteratively solved
over the MD simulation time. The molecular system can be coupled to external
variables. Indeed, an additional term Vbias(r), may be used either to limit particle
motions or to enhance the conformational sampling.
In the following part of the thesis, the description of the systems is based
on the formalism of classical physics. By contrast with quantum physics where
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electron positions around a nucleus are considered, atoms are represented as
spheres with a fixed volume and a fixed partial charge.
1.3.1 The bonded interactions
Two different AMBER forcefields (AMBER99sb and AMBER99sb-ILDN) have
been used in this thesis. Therefore, the description below is based on a specific
formalism.
The bonded interactions are a combination of four terms:
V bonded = V bond + V angle + V dihedral + V improper (1.12)
They describe the bond elongations, the angle deformations and the torsions for
the periodic and improper dihedral angles.
1.3.1.1 Bond-stretching term
The energy of a covalent bond between two atoms is calculated by analogy





2 (bn − b0n)
2 (1.13)
where Nb is the total number of covalent bonds, bn is the distance between two
atoms, b0n is the equilibrium distance and kbn is the force constant which is
determined by comparing the experimental data after a conformational search
1.3. Classical Force Fields 19
strategies. The two last parameters depend on the type of atoms i and j and the
force fields.
1.3.1.2 Bond-angle bending
The bending potential captures the energy of the valence angle deformations
between three atoms i, j and k joined by covalent bonds. This term is also






2 (θijk − θ0)
2 (1.14)
where θ is the angle between three atoms i, j and k, θ0 is the reference angle and
kθ is the force constant.
1.3.1.3 Torsion term
The third energy term concerns the φ dihedral angle of two plans defined
by three covalent bonds and involving four atoms. A dihedral angle with a
value of 0 is called cis and a dihedral angle with a value of 180 is called trans.
The corresponding potential is defined as a Fourier series expansion around the





2 [1 + cos(nφn − γn)] (1.15)
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where Vn is the rotational energy barrier, n is the number of minima in a complete
rotation and γ is the phase angle.
A similar equation is used to calculate the energetic contribution of the improper
dihedral angle potential.
1.3.2 The nonbonded interactions
The interaction between non-bonded atoms are described by the sum of
two different energetic potentials (Equation 1.16). The non-bonded term is in
principle calculated for all pairs of atoms but a number of pair-wise interactions









Van der Waals interactions are described by a Lennard-Jones Potential:











where rij is the distance between the two atoms i and j, the ε (kcal.mol−1) and
σ (Å) are dependent on the atom type i and j.
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The first term characterizes the repulsion between two atoms due to Pauli’s
exclusion principle while the second is an attractive term capturing the London
dispersion forces. The Lennard-Jones potential is calculated for atoms separated
by at least three covalent bonds. For atoms at exactly three covalent bonds from
each other (interactions 1-4), the van der Waals energy is frequently divided by
two.
1.3.2.2 Electrostatic Potential
As for the van der Waals interactions, the electrostatic potential is calculated
between charged atoms separated by at least three covalent bonds. The potential







where qi and qj are the partial atomic charges of the atom i and j, ε is the effective
dielectric constant and rij is the distance between the two atoms i and j.
1.4 Molecular Mechanics & Dynamics
MD is an intuitive method to explore the potential energy surface of a
protein. Historically, one of the first molecules of interest, the small protein
bovine pancreatic trypsin inhibitor, which has been studied by MD was in 1977.67
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This technique is still broadly used in many different fields. The following section
aims to give an overview of the methodology.
1.4.1 Energy minimization
Prior to perform a MD simulation, an energy minimization step of the
potential energy of the system (1.6) is often essential to avoid too large molecular
forces in the starting protein conformation that may encourage the exploration
of low probability conformations. Usually, such high forces cause the numerical
integration of the equations of motions to crash. Several algorithms can be used
to perform a potential energy minimization such as the steepest descent (SD),
conjugate gradient or quasi-newtonian method. Only the first approach has been
used in this thesis. As with the conjugate gradient, SD is a gradient method using





The system is almost exclusively ‘pushed down’ to reach the nearest local minimum
on the potential energy surface. The conformation r(tn+1) at the n+1 step of
the minimization step is computed by calculating the forces f(tn) according to
equation 1.7 for a given set of atomic coordinates r(tn).




where hn is the maximum displacement and fn is the force at the step n.
| max(fn) | is the maximum of the absolute values of the force components.
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Then, the potential energy and the forces are calculated for the new atomic
positions at the step n+ 1.
The new conformation is accepted if Vn+1 < Vn and hn+1 = 1.2hn. Otherwise, the
new atomic positions are rejected and hn = 0.2hn. Calculations stop when the
maximum of the absolute values of the force components (gradient) is smaller than
a specified value or if the predefined maximum number of minimization steps has
been achieved. While energy minimization approaches are effective at finding the
nearest local energetic minimum from a starting conformation, they are unable
to overcome energetic barriers. For this reason, MD simulations provide a more
efficient way to sample low energy protein conformations.
1.4.2 Molecular dynamics
MD simulations are today widely used in order to study the structure,
dynamics, and some thermodynamic aspects of molecular systems. Several algo-
rithms, such as the leap-frog or Verlet integration, are implemented in GROMACS
for integrating Newton’s equations of motion (Equations 1.7, 1.9 and 1.10). Only
the leap-frog method was used in the context of this thesis.
1.4.2.1 Integrators
In this section, a quick description of the Leap-frog and Verlet algorithms is
given. The first one is based on the difference of two Taylor series of the velocity
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vi(tn −∆t/2) and vi(tn + ∆t/2) at a time t = tn:




Likewise, the atomic positions at a time tn are determined as:
ri(tn + ∆tn) = ri(tn) + ∆tvi(tn +
∆tn
2 ) (1.22)
The above two equations are used to integrate the equations of motion over
the time and generate a trajectory. In order to get the position-update relation
using the Verlet integrator, velocities vi of the Equations 1.21 and 1.22 has to be
removed. In addition, the time tn has to be replaced by tn −∆t in Equation 1.21.
Therefore, the new atomic positions are given by:




The simulation time is directly dependent on the integration step ∆t. The
time step has to be smaller than the fastest motion of the system to be able to
capture it. Rotations of hydrogen-bonded hydroxyl groups limit usually the time
step in the order of the femtosecond.68
In a standard MD simulation, the total energy E of the molecular system is
constant. Generally, the total number of atoms (N) and the volume (V ) of the
simulation box are also fixed. This type of simulation is called microcanonical
or NV E simulation. However, in order to perform simulations under conditions
that are the most similar to experiments, it may be better to maintain a constant
temperature rather than energy (NV T simulations or canonical) and a constant
pressure instead of the volume (NPT or isothermal-isobaric). For NV T and NPT
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simulations, it is necessary to use a thermal or/and a pressure bath respectively.
1.4.2.2 Temperature Coupling
Several methods for controlling the temperature during MD simulations
have been developed.69 In the case of the Berendsen thermostat, the system is
weakly coupled to a heat bath.70
dT
dt
= T0 − T
τT
(1.24)
The control of the temperature can be achieved by modifying the velocities of the
particles of the system using a velocity rescaling factor λ (Equation 1.25).





where ∆t is the integration step of the MD simulation and τ is the coupling
constant. τ can be adjusted in function of the system. This constant has to be
strong enough to maintain the average temperature of the system at reference
value T0 but without perturbing the dynamics.Usually for a time step of 3 fs, a
coupling constant between 0.5 and 1.5 ps is sufficient. This thermostat suppresses
fluctuations of the kinetic energy of the system. Therefore, the conformational
sampling is biased and the produced trajectories are not consistent with the
canonical ensemble. Recently, the Berendsen thermostat was modified using a
stochastic procedure to yield canonical ensembles.71 All simulations discussed in
this thesis were performed using this stochastic Berendsen thermostat. In this
velocity rescaling thermostat, an external stochastic term is used to correct the
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kinetic energy distribution:










where K is the kinetic energy, Nf is the number of degrees of freedom and dW a
Wiener noise.
1.4.2.3 Pressure Coupling
Different barostats can be used to maintain the simulation at constant
pressure.70, 72–74 They act by modifying the vectors of the simulation box and
rescaling the atom coordinates. Three different methods are available:
• isotropic pressure coupling: modifications are applied uniformly to the
system.
• semi-isotropic pressure coupling: modifications are applied indepen-
dently in the x-y and z dimensions.
• anisotropic pressure coupling: modifications are applied independently
in all directions.
In the major part of the thesis, simulations were performed in implicit solvent.
Therefore, it was not necessary to define a simulation box and pressure coupling
is not needed. As an example, the Berendsen barostat is described below. The
term added to the equations of motion for maintaining a constant pressure is
similar to the temperature coupling:
dP
dt
= P0 − P
τp
(1.27)
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where τp is the pressure coupling constant. The pressure can be expressed as a










where rαβ is the distance between the center of mass of the molecules α and β
at the time t and Fαβ is the force acting on the center of mass of the molecule
α induced by the molecule β. Because the control of the pressure at constant
temperature is linked to the volume by the isothermal compressibility κT , the
pressure coupling is performed by adjusting the atomic coordinates and also the
size of the simulation box with a correction factor µ (Equation 1.30).
µ = [1− κT
∆t
τp
(P0 − P )]
1
3 (1.30)
The Parrinello-Rahman barostat was also used in this thesis in the chapter 3.72
This anisotropic approach allows to change the vectors of the simulation box but
also its shape. Even if this method is slower than the Berendsen weak coupling,
it maintains canonical ensemble and is more adapted to predict thermodynamic
properties.
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1.5 Enhanced Conformational Sampling
Most physical and chemical properties of a system can be interpreted
directly or indirectly from free energy changes in the system. For example, the
conformational preferences of a molecule or a protein, the solvation constants of
association or dissociation of complexes are directly related to the difference in
free energy between two states.
1.5.1 Free Energy Calculations
The free energy is a thermodynamic state function. For a system with a
volume V that is defined by N particles at a temperature T , the Helmholtz free
energy is given by:
F = E − TS (1.31)
where E is the total energy of the system and S is the entropy.
In the same way, at constant pressure (P ), the Gibbs’s free energy is expressed
as:
G = F + PV = E + PV − TS = H − TS (1.32)
where H is the enthalpy.
According to statistical mechanics, the free energy for a discrete states system is
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where κB is the Boltzmann consant.







− κBT lnQ (1.35)
When those equations are applied in Cartesian coordinates to a system made up



















Q is a statistical property directly related to the probability of finding the system
of interest in a given state and the ensemble of the phases accessible to the system.
To obtain a good estimate of the absolute free energy, it would be necessary to
sample the entire ensemble of conformations and calculate the partition function
of the system. However, this approach is not possible because the system can
actually adopt a very large number of conformations while all simulations or
experiments lead to the sampling of a finite number of phases. The free energy
difference between two states of the system is easier to calculate. It is obtained
by the ratio of the probability of finding the system in the two considered states.
Several simulation techniques have been designed to compute relative free energy
changes such as thermodynamic integration, free energy perturbation or umbrella
sampling.75
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When one is interested in a reaction or physicochemical processes associated
with a reaction coordinate s, it is interesting to compute the probability of the
conformations observed for different values of s. s is also known as a collective
variable (CV) and can describe any aspect of the system such as the distance
between two center of mass, a dihedral angle or a helical structure. The probability
distribution of the system along s is given by:
ρ(s) =
∫











where Q is the partition function of the system and V (r) is the potential energy
of a given conformation of the system. The term Qρ(s) is actually the partition
function of the system where all the degrees of freedom of s are fixed at a constant








where F is the free energy and F (s) is the partial free energy according to s or
Landau’s free energy (Equation 1.41)
F (s) = −κBT lnQρ(s) (1.41)
Partial free energy is a function of s, which is directly related to the probability
of sampling conformations for a specific value of s. In practice, Equation 1.40 is
used to calculate the free energy (Equation 1.42).
F(s) = −κBT (ln p(s)− lnQ) (1.42)
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Because Q is independent of s, the probability density function p(s) can be back-
computed from a MD simulation by calculating the histogram of the collective
variable along the simulation.
1.5.2 Umbrella Sampling
Quite frequently, classical MD simulations are unable to sample a significant
range of values of a collective variable. The intramolecular potential or the
system environment can induce constraints such that only a small part of the
domain of variation of the reaction coordinate is explored. In addition, the
conformational sampling is also limited since the simulation time is not infinite.
Equation 1.42 does not allow to obtain directly the variation of free energy between
the equilibrium state and a conformation of interest. The method of umbrella
sampling (US) introduces an external energetic term to the potential energy of
the system according to a CV.76 In general, the bias is defined as a quadratic
function:
V (r; s)bias = k2(s− s0)
2 (1.43)
where k is the force constant and s0 is the equilibrium position of the bias.
Simulations performed using such methodologies are called biased simulations.
By selecting different s0 values, one is able to sample specific regions of the
conformational space described by the CV. A simulation corresponding to a given
value of s0 is called a window and the free energy surface along the CV is called
the potential of mean force (Figure 1.4).




Figure 1.4: Example of umbrella sampling simulations. The real potential energy
surface is depicted in blue (plain line). The potential energy surface corresponding to
each window of s are represented with dashed lines.
necessary to remove the contribution of the bias to the computed probabilities.
The unbiased distribution is given by equation 1.38.
However, US simulations provide only the biased distributions along the CV:
P (s)b =
∫








Because the bias potential depends only on the collective variable s, the previous
equation can be expressed as:
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At constant pressure, the free energy along s can be calculated as follows
G(s) = −κBT lnP (s)bias − V (r; s)bias + Fi (1.48)
Where Fi is a constant defined by









To be efficient, it is necessary to define accurately the range of each windows.
Therefore, US is mainly relevant when the system of interest is well known and
a substantial amount of experimental data are available. Otherwise, techniques
such as metadynamics may be more attractive.
1.5.3 Metadynamics
The fundamental idea of metadynamics is to prevent a system from revisiting
a part of the conformational space that has been already explored. The algorithm
allows eliminating the problem of rare event sampling and to reconstruct the
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multidimensional free energy profile of complex systems by introducing an history-
dependent bias potential in a MD simulation defined as a small Gaussian:










where ω is the height and δσ the width of the Gaussians, τG is the rate of their
deposition, s(x) and s(x(t′)) are the value of the collective variable.
One of the advantages of metadynamics is the possibility to fill up rapidly
a local minimum and allow the exploration of the next lowest-energy minimum
(Figure 1.5). The value of ω, δσ and τG are crucial in this method because they
influence directly the efficiency but also the accuracy of simulations.
The forces derived from the non-Markovian potential VG act directly on the
cartesian coordinates of the system, in addition to the forces fVi exerted by the
potential energy V . During a metadynamics simulation, the force applied on an
atom i of the system is given by:












The historical potential VG penalizes visited areas of the conformational space
encouraging the system to explore new states. VG allows to speed up the simulation
of rare events. The system escapes from a local minimum through the nearest
transition state encountered. The ability to reconstruct the free energy profile from
metadynamics simulations is based on the assumption that FG(s, t) = −VG(s, t)
is an approximation of F (s) in the region sampled by s(xG(t′)). In this way, after











Figure 1.5: Illustration of a metadynamics simulation.The potential energy surface of
the protein is represented in blue. The gaussian added every τ time steps are depicted
in red. This figure illustrates how the system can easily escape from a local minimum
and explore other conformations of interest.
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a sufficient time when the CV has converged, the free energy profile is given by:
lim
x→+∞
FG(s, t) ∼ F (s) (1.52)
Metadynamics is particularly efficient to explore the conformational space
of system by biasing the simulation using up to three CVs. For more complex
systems, other variants such as bias exchange metadynamics may be preferred.77
1.5.4 Bias-Exchange metadynamics
In this thesis, the bias-exchange variant of metadynamics was also used.77
The approach entails running a set of molecular dynamics simulations. The
sampling of molecular conformations in each simulation is biased by a history-
dependent potential as described above. Exchanges between the biasing potentials
used in the different CVs are periodically attempted according to a replica exchange
scheme. The swap is accepted according to the Metropolis criterion. BEMD
has been shown to allow exploring complex free energy landscape such as the
folding free energy landscape of small proteins and protein/ligand complexes on
timescales of a few dozen ns.78, 79
1.5.5 Weighted Histogram Analysis Method
When a single window was defined to bias a system along a CV, equation
1.48 is sufficient to reconstruct the free energy profile (FEP). Otherwise, the FEP
is reconstructed within a constant (Fi) and computational approaches may be used
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to connect profiles obtained from different windows (Figure 1.4). The constants Fi
(equation 1.49) correspond to the free energies associated with the introduction of
the biased potential V (r; s)bias. In this thesis, the Weighted Histogram Analysis
Method (WHAM) was used to reconstruct the FEP from biased simulations
along a CV (s) depending on the cartesian coordinates r of the system.80, 81 The
overall distribution P u(s) is obtained by calculating a weighted average of the
distributions of each window, minimizing the statistical error.
Considering Nw as the number of biased simulations and ni as the number
of stochastically independent events used to construct the biased distribution
P bi (s), the overall unbiased distribution P u(s) can be expressed according to the





ni exp[−β(V (r; s)biasi (s)− Fi)]∑Nw
j=1 nj exp[−β(V (r; s)biasj (s)− Fj)]
(1.53)







j=1 nj exp[−β(V (r; s)biasj (s)− Fj)]
(1.54)
The constants Fj can be directly estimated from the unbiased distribution P u(s):
exp(−βFj) =
∫
P u(s)ds exp(−βV (r; s)biasj (s))ds (1.55)
At each step of the process, the Equations 1.54 and 1.55 have to be solved. The
WHAM approach can be easily generalized to more than one CV.
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2
Protein-Ligand Interactions
This chapter gives an overview of the protein-ligand binding process with a focus
on the specific case of intrinsically disordered proteins.
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According to quantum mechanics, a system of one or more particles is
defined by its wave function Ψ (also called state function). The Schrödinger





where i is the imaginary unit, ~ is the reduced Planck constant and Ĥ is the
Hamiltonian operator.
In the case of a stationary system, which is not explicitly time-dependent, the
Schrödinger equation can be expressed as:
EΨ = ĤΨ (2.2)
where E is the energy of the stationary state.
In the case of a molecular system composed of M nuclei and n electrons,





































where r are the coordinates of nuclei and electrons, z is the charge the nucleus, e
is the charge of an electron, m is the mass and ∇ is the Laplace operator.
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Several approaches have been introduced in order to provide an accurate
description of small systems within reasonable time.1 However, they are computa-
tionally demanding and may require very important resources even for systems of
a few atoms. Therefore, as described in the previous chapter, interactions between
atoms and molecules are frequently modeled using a classical formalism and
different equations are needed to model different aspects of quantum chemistry.
This chapter gives an overview of the protein-ligand binding process with a focus
on the specific case of intrinsically disordered proteins (IDPs).
2.1 Non-covalent interactions
The functioning of biological systems is based on folding and recognition
mechanisms involving non-covalent molecular interactions. At the protein level, a
subtle balance between attractions and repulsions controls the three-dimensional
(3D) structure of a protein and therefore also its activity in the cell. In this part,
three kind of non-covalent interactions are discussed.
2.1.1 Electrostatic Interactions
The electrostatic interactions between two charged molecules can be de-
scribed by Coulomb′s law:
V Electrostatic = qiqj
π4εrij
(2.4)
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where qi and qj are the partial atomic charges of the atom i and j, ε is the effective
dielectric constant and rij is the distance between the two atoms i and j.
This electrostatic potential is inversely proportional to the distance between
the two charges. It is important to note that the relative permittivity of water
is about 80 at room temperature, which means that the ionic interactions are
considerably reduced in aqueous medium compared to air (ε = 1) causing the
dissolution of most salt crystals in water.









where NP and NL are respectively the number of partial atomic charges of the
protein and the ligand.
2.1.1.1 Van der Waals Interactions
Interactions between neutral molecules are based on electrostatic interactions
between permanent dipoles and/or induced dipoles. These forces are responsible
for multiple interactions between neighboring atoms and are also called van der
Waals forces. We can distinguish three kind of van der Waals interactions: Keesom
force, Debye force and London dispersion force.
Keesom force When, in a neutral molecule, the center of gravity of the
positive charges is different from the center of gravity of the negative charges,
the molecule is considered as polar and has an electric dipole moment µ directed





Figure 2.1: Illustration of the interaction between two permanent dipoles.
from the negative charge to the positive charge. Two polar molecules of non-zero
dipole moments can find favorable positions to maximize the attraction between
them (Figure 2.1).





where µ is the dipole moment, ε0 is the permittivity of free space, εr is the
dielectric constant of surrounding material, κB is the Boltzmann constant and T
is the temperature.
Debye force A polar molecule with a permanent dipole moment (µ) in-
duces a rearrangement of the electron cloud of neighboring apolar molecules under
the effect of the electric field (E). The electron cloud deformation is characterized
by the polarizability of the molecule, which increases with the number of electrons.
This non polar molecule acquires an induced dipole moment:
µi = αE (2.7)





Figure 2.2: Illustration of the interaction between a permanent dipole (µ) and an
induced dipole (µinduced).
where α is the polarizability of the apolar molecule.
This induced dipole interacts with the permanent dipole of the first molecule as
shown in figure 2.2.
The energy corresponding to dipole-dipole induced interactions is expressed as:





London dispersion force In the case of non polar molecules, the electron
cloud is symmetrically distributed and no dipole moment is observed. However,
the electron motion may create an instantaneous dipole moment able to polar-
ized neighboring apolar molecules leading to an induced dipole moment. Both
instantaneous dipoles vary rapidly over time and can interact together as shown
in Figure 2.3.
The London dispersion is described the following equation:





Figure 2.3: Illustration of the interaction between an instantaneous dipole (µ∗) and
an induced dipole (µinduced).





where I is the ionization potentials of the molecule.
The London forces are very weak interactions. However, the large number of
interatomic contacts in protein-ligand complexes make that dispersion forces may
play an important role in the binding process.
Van der Waals radius and energy By considering only van der Waals
forces as attractive, it is not possible to explain the existence of an equilibrium
intermolecular distance. Repulsive forces are also involved in the formation of
protein-ligand complexes controlling the impenetrability of the molecules. Van
der Waals interactions are described by a Lennard Jones potential:











Figure 2.4: Illustration of a Lennard-Jones potential (Equation 2.10).
where rij is the distance between the two atoms i and j, the ε (kJ.mol−1) and σ
(Å) are dependent on the atom type i and j.
This potential is illustrated in figure 2.4.
Van der Waals interactions are weak interactions (around several kJ.mol−1) but
can significantly stabilize a protein-ligand complex.
2.1.1.2 π interactions
π interactions are mainly due to dispersion forces.2, 3 Different kind of π
interactions can be observed such as:
1. cation-π system: interactions between the positive charge of cations (or a
metal) and the face of a π system
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2. Polar-π system: interactions of a polar molecule and the multipole moment
of a π system
3. π stacking: interactions between two aromatic systems (‘face-to-face’)
Non-covalent interactions involving π systems are very important in many biolog-
ical events such as protein-ligand recognition.2
2.1.2 Hydrogen-bond
Hydrogen-bonds are also mainly electrostatic interactions. They involve
dipole/induced-dipole interactions even if other phenomena such as polarization
or dispersion also contribute to the total energy of hydrogen bonding. During
this process, a hydrogen atom attached to an electronegative atom (donor) is
carrying a fraction of positive charge that polarize another molecule with a lone
pair (acceptor). These electronegative atoms are usually fluorine, oxygen, or
nitrogen. A hydrogen attached to a carbon atom may also participate in hydrogen
bonding if the carbon atom is bound to electronegative atoms. The strong
interaction between the dipole and the induced dipole involves the alignment
of atoms as is the case for van der Waals forces. Hydrogen bonding is highly
directional and usually stronger than van der Waals interactions (between 10 to 30
kJ.mol−1). Nevertheless all hydrogen bonds do not have the same characteristics.
As suggested by Jeffrey, they may be classified into three different categories
according to their binding energy and directionality (Table 2.1).4
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Strong Interactions Medium Interactions Weak Interactions
Kind of




kJ.mol−1 60-160 15-60 < 15
Bond Lengths (r)
Å 1.2-1.5 1.5-2.2 2.2-3.2
Bond Angles (θ) 175− 180◦ 130− 180◦ 90− 150◦




Figure 2.5: Representation of a hydrogen bond according to the parameter r and θ
given in Table 2.1 .
2.1.3 Hydrophobic Interactions
Hydrophobic interactions play a crucial role in many biological processes
such as protein folding or assembly of biological membranes.5–7 Water is char-
acterized by a strong internal cohesion that is characterized by a high enthalpy
of vaporization and a high surface tension. Therefore, an apolar molecule tends
to avoid contacts with water by interacting with the non polar parts of other
molecules. This association partially offsets the unfavorable free energy due to the
solvation of such molecules by reducing the area accessible to water and creating
strong van der Waals interactions.
The hydrophobic effect is a complex process that is still not well char-
acterized. Hydrophobic interactions appear to be related to the occurrence of
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transient dipoles, water molecule rearrangements.8–10 Despite their apolarity, the
electron clouds of two adjacent hydrophobic molecules interact in such a way that
partial charges of opposite sign appear. Therefore, London forces are the main
process characterizing the hydrophobic effect even if other parameters are also
involved.11
2.2 Thermodynamics of ligand binding
In the context of this thesis, a molecular receptor is a protein providing
a structural arrangement of its functional groups promoting interactions with
another molecule called a ligand. These interactions may lead to the formation of
a reversible complex because no covalent bonds are formed. In some cases, the
receptor conformations are so specific that favourable interactions can only be
formed with a few ligands (principle of selectivity). The formation of a reversible
receptor-ligand complex is usually represented as a chemical equilibrium. This
state is reached when the concentrations of both reactants and products do not
change over time. Actually, the equilibrium reflects a compensation between the
reaction rates of the forward and backward reactions. A simplified view of the
formation of a complex involving only one protein receptor (R) and one ligand
(L) can be expressed as follows:
R + L −−−−⇀↽ − RL (2.11)
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This chemical process is often characterized by the dissociation constant of the




The lower the Kd is, the higher is the affinity between the ligand and its receptor.
Kd is directly related to the standard Gibbs free energy of binding ∆G0 by:
∆G0 = RT ln Kd
C0
(2.13)
where R is the gas constant, T is the temperature and C0 is the standard state
concentration of a dilute solute (1 mol.L−1).
A negative value of the ∆G0 means that the free energy of the complex is lower
than the free energies of each partner in an unbound state. Therefore, the
formation of the complex is spontaneous. This free energy can also be expressed
as the sum of two terms:
∆G0 = ∆H − T∆S0 (2.14)
where ∆H is the variation of enthalpy and ∆S0 is the variation of entropy.
The enthalpy change in this process is related to changes in non-covalent
interactions. If ∆H < 0, the system is considered more stable because the
bound state involves more interactions (or fewer but stronger) than the free state.
The entropy change captures if the system becomes more ordered (∆S0 < 0)
or less ordered (∆S0 > 0) after the formation of the complex. In the context
of protein-ligand binding, this property is usually associated with the solvation
entropy change, the protein/ligand conformational entropy changes, and the
protein/ligand rotational and translational entropy changes.12 If an increase of
the disorder is observed, the reaction is entropically favorable. Indeed, if ∆S0 > 0
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and ∆H < 0, then ∆G0 could be negative. In general, the presence of the ligand
stabilizes the protein and ∆S0 becomes negative. If this entropic cost is not offset
by a decrease of the enthalpy term, ∆G0 will be close to 0. This characteristic
allows proteins to be involved in rapid association/dissociation processes.
The affinity characterizing receptor-ligand interactions is a subtle balance
between the entropy term and the enthalpy term. Electrostatic interactions play
a fundamental role in the stability of the complex. They include salt bridges,
hydrogen bonds, π-π interactions, dipole-dipole interactions and also interactions
with metallic ions. Hydrogen bonds are due to the attraction of a hydrogen atom
bonded to an electronegative atom (donor) by another electronegative atom or
a π-electron system (acceptor). The electronegative atoms are usually fluorine
(F), nitrogen (N) or oxygen (O). The distance between donor and acceptor atoms
is between 2.5 Å and 3.2 Å, and the bond angle is between 130◦ and 180◦. The
strength of the hydrogen bond depends directly on the environment, and more
especially on the dielectric constant ε. The dielectric constant of water (or the
relative permittivity), as well as that found at the protein surface, is estimated at
80. However, inside the protein, ε is evaluated between 1 and 20.13 Furthermore,
the dielectric constant near polar groups and flexible regions is higher than in
apolar regions. Thus, in the context of ligand binding, hydrogen bonds buried
in the protein are generally more important than those exposed to the solvent.
Before the binding process, protein and ligand are only interacting with the
solvent. In solution, the functional groups of each species are involved in hydrogen
bonding with water molecules. The difference between the free energies of these
contributions and the hydrogen bonds formed in the complex determines whether
these hydrogen bonds contribute favorably to the formation of the complex or not.
Indeed, the presence of polar groups in the protein/ligand molecules that are not
involved in hydrogen bonding in the complex is highly unfavourable to complex
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formation.14 In contrast, the desolvation of apolar parts releases highly ordered
water molecules increasing the entropy. This increase in entropy of the solvent due
to the burial of the protein apolar regions is called the hydrophobic effect.5 The
hydrophobic effect is generally the major force that stabilizes the complex, while
the Coulomb interactions and hydrogen bonds rather intervene in the specificity
of receptor-ligand interactions. The buried hydrophobic surface can be correlated
to the free energy of binding with values between -0.11 to -0.24 kJ.mol−1.Å−2.
For example, the burial of a methyl group representing a surface of 25 Å2 may
correspond to a contribution of -2.75 to -6 kJ.mol−1. Hydrophobic interactions are
responsible for roughly 80% of the free energy involved in molecular recognition
events.15 Beside the increase in the solvent entropy, the binding process involves
a decrease of the solute entropy. The change in free energy due to the loss of side-
chain conformational entropy (T∆S) was found to vary from 0 (alanine, glycine,
proline) to 8.7 kJ.mol−1 (glutamine) with an average value of 3.7 kJ.mol−1.16
The knowledge of the enthalpy and the entropy terms allow a better un-
derstanding of the interactions compared to the dissociation constant. Indeed,
processes having similar ∆G0 may have very different ∆H and ∆S0. Carbonic
anhydrase II is a good example illustrating this problem. The enzyme catalyses
the transformation of carbon dioxide in water to bicarbonate with the release
of protons. Several small molecules are known to inhibit carbonic anhydrase
II such as 4-carboxybenzene-sulfonamide and 5-dimethylamino-1-naphthalene-
sulfonamide. The chemical structures and the binding thermodynamic properties
of both ligands are represented in Figure 2.6.17Interestingly, those two ligands
show a similar free energy of binding and thus a comparable dissociation constant.
However, different enthalpic and entropic components are observed. In both
cases, the enthalpy is favourable whereas from an entropy point of view, the first
interaction is unfavourable while the second is favourable. This analysis reflects



























Figure 2.6: Chemical structure of two different inhibitors of carbonic anhydrase II
with different thermodynamic properties determined by isothermal titration calorimetry
at 298 K. CBS: 4-carboxybenzene-sulfonamide, DNSA: 5-dimethylamino-1-naphthalene-
sulfonamide.17
that the driving forces leading to the complex formation are different.
2.3 Measuring binding free energies
As described in the previous section, the logarithm of the dissociation
constant is proportional to the Gibbs free energy of binding (Equation 2.13). Sev-
eral methodologies, such as isothermal titration calorimetry or surface plasmon
resonance, are commonly used to experimentally measure Kd and other thermody-
namic properties.18, 19 Such approaches allow to measure Kd values between 10−2
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to 10−10 M, which corresponds to values of the free energy between -10 and -70
kJ.mol−1 at a temperature of 298 K. A change in the free energy of 5.7 kJ.mol−1
at 298 K induces a perturbation of the dissociation constant by a factor of ten.
The dissociation constant is not the only parameter that can be measured to
describe the affinity between a ligand and its target. Ki and IC50 characterize the
inhibition of a protein. Ki represents, in the case of an enzyme for example, and
more especially in the ideal conditions of the Michaelis-Menten model (∆G0 << 0
and a concentration of substrate much larger than the concentration of product),
the inhibition constant.20 The half maximal inhibitory concentration , noted IC50
allows to characterize the effect of a small molecule on the biological activity of
a target. When measuring those values, it is essential to perform experiments
under such conditions that the target is a limiting factor, which means that the
dynamic phenomena associated with the target must be a linear function of the
concentration of the target. The inhibitor binds the enzyme either alone or to
the enzyme interacting with its substrate, depending on whether the inhibitor
is competitive or non-competitive. The dissociation constant at equilibrium is
called Ki and corresponds to the concentration of inhibitor required to saturate
half of the enzyme’s active site. Therefore, Ki allows to measure the affinity of an
inhibitor for a specific enzyme. The action of a competitive inhibitor on enzyme
activity is measured by the IC50. The binding process of a ligand to its receptor
is similar to the fixation of a substrate to the enzyme, except that the binding
phenomenon is not followed by a change in enzymatic activity. In the case of a
reversible and non cooperative binding process, the Cheng-Prusoff relationships
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where Ki is the binding affinity of the inhibitor, IC50 is the functional strength
of the inhibitor, [S] is the substrate concentration and Km is the concentration
of substrate at which enzyme activity is at half maximal (Michaelis-Menten
constant).
2.4 Protein flexibility in ligand binding
In order to recognize specifically a ligand, a protein possesses a suitable
binding site. Based on this observation, a first model explaining the mechanism
of binding of a ligand to a protein was proposed by Fischer in 1894 (Figure
2.7 A).22 In this approach so-called ‘lock and key’, proteins and ligands are
considered as rigid bodies. Although the model is applicable to some extent
to large number of complexes, it does not reflect the general behaviour of the
different protagonists in solution. For this reason, the induced-fit model was
introduced (Figure 2.7 B, left).23 First, the ligand interacts with a conformation
of the target. Then, during the binding process, each partner may adjust its
structure to maximize the binding affinity. This mechanism dominated the view
of of protein flexibility until a new vision of protein folding emerged during the
1990s.24, 25 According to the rate-determining step of the binding process, several
models such as the conformational selection or the population-shift mechanism
were proposed.26–28 Those approaches are based on the unbound state, which
exists as a set of conformations called conformational isomers or conformers. The
ligand can select one or few conformations from the equilibrium ensemble to form
a complex (Figure 2.7 B, right).
A large number of systems where protein flexibility plays a crucial role in the







Figure 2.7: Illustration of the most common models describing the binding process
between a protein (receptor) and a ligand. A) Lock and key model. B) Induced fit
model (left panel) and Conformational selection (right panel).
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binding process have been described in the literature.29 This flexibility may involve
small or large structural rearrangements. For instance, motions of few amino
acids located near the active site of acetylcholinesterase have been reported.30
Because of its involvement in the memorization process and Alzheimer’s disease,
this enzyme has been extensively studied.31, 32 Using MD simulations, the authors
were able to identify two residues of the active site showing a high flexibility. The
findings from this study suggest that the equilibrium ensemble of this protein is
composed of a large number of distinct conformations, and different ligands select
a different subset of those conformations upon complex formation.30
Another interesting example is given by the antibody SPE7.33 Free SPE7
exists in two very different conformations (Ab1 and Ab2). Those isomers are able
to interact with two structurally different ligands forming two distinct complexes
(Ab3 and Ab4). Initially, the binding mode appeared to follow the mechanism of
the conformational selection. However, the authors suggest that it is possible to
induce Ab4 starting from Ab1 and Ab3 starting from Ab2. This observation tips
the scale in favor of the induced-fit model. This study highlights the potential
role of conformational diversity in cross-reactivity leading to autoimmune diseases
and allergies.34
2.5 Intrinsically Disordered Proteins
The structure and function relationships of proteins occupy a central and
fundamental position in biology and have been studied extensively. For a long
time, it has been accepted that the three-dimensional (3D) structure of a protein
was only dictated by its amino acid sequence and also that this specific structure
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was related to a single function.36 However, in the 1990s, the discovery of
proteins that are not or poorly ordered have led many to question this dogma.
The development of spectroscopic techniques has accelerated the study of 3D
structures of such disordered proteins. The idea that proteins could be active
while being unstructured became increasingly stronger. Thus, in 1999, Dyson et al.
suggested that a protein may be both partially (or completely) unstructured and
active.37 Since then, intrinsically disordered proteins (IDPs) have been studied
extensively and a database called Disprot was created.38 In 2014, 694 proteins
and 1539 disordered regions were referenced. Proteins that contain a segment
of at least 30 consecutive disordered residues in their native state are typically
classified as IDPs (intrinsically disordered proteins).39 In mammals, around
50% of the proteins can be considered as partially or completely disordered.40
The considerable flexibility of IDPs facilitates interactions with a broad range
of proteins and explains why IDPs often play key roles in important cellular
processes such as signaling or transcription.41, 42 In addition, IDPs are involved
in many cancers, cardiovascular and neurodegenerative diseases.43
The flexibility of IDPs is due to their singular amino acid composition.
Globular proteins are well structured, and usually composed of hydrophobic
residues forming the core of the protein whereas polar and charged residues are
more frequently localized at the protein surface. It is now well accepted that IDPs
are significantly enriched in proline , glutamic acid, lysine, serine and glutamine
while they are depleted in tryptophan, tyrosine, phenylalanine, cysteine, isoleucine,
leucine, and asparagine.44 Furthermore, they have a high net charge and low
hydrophobicity, precluding the formation of a hydrophobic core and promoting
instead an extended conformation by electrostatic repulsion between charged
groups. In solution, by contrast with globular proteins, IDPs do not adopt one
dominant structure, but oscillate between structurally diverse conformations of
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Figure 2.8: Illustration of the energy landscape of a globular protein (A) and an
intrinsically disordered protein (B).
comparable low energies. This translates into a flat energy landscape (Figure
2.8).45
2.6 IDPs-ligand Interactions
IDPs have just started to be considered as druggable.46 The chapter section
is focused on the mechanisms of small-molecules binding to IDPs. Molecular
recognition between an IDP and a partner protein can involve a disorder-to-order
transition through a coupled folding upon binding mechanism, which produces
high-specificity low-affinity complexes (Figure 2.9).47–49 There are, however,
several examples of IDPs that remain disordered upon complex formation.50
IDPs are attractive therapeutic targets as they are often implicated in a broad
range of diseases, such as cancers, cardiovascular disease or neurodegenerative
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diseases. However, the considerable flexibility of IDPs presents a challenge for drug
discovery approaches.43 Owing to their lack of a well-defined tertiary structure,
it is generally not possible to determine the structure of isolated IDPs. So far,
structure-based approaches to inhibit IDPs have targeted either partner proteins
that are ordered or ordered complexes, in those cases where IDPs fold upon
binding. For instance, the p53 tumor suppressor is an IDP that is involved in
the progression of more than 50% of human cancers.The transcriptional activity
of p53 is tightly regulated by its partner protein MDM2 (murine double minute
2) and cancer cells often overexpress MDM2 to inhibit p53 function.51 As the
p53-binding domain of MDM2 is folded, crystal structures can be readily obtained
and have been exploited to design several classes of small-molecule inhibitors
of p53-MDM2.52 Some of the most successful inhibitors have advanced into
clinical trials.53 However, several protein-protein interactions involve two IDPs
whose structure cannot be solved in isolation. Even in those instances where two
IDPs mutually fold upon binding, the structure of the complex may not reveal
pockets to which small molecules could readily bind. Thus a more general route
to inhibiting IDP function would be to directly target their disordered state with
small molecules. Historically, this approach has not been considered feasible.46
However, this view has been challenged in recent years, with the realization that
several small molecules inhibit IDP function by binding to their unfolded state.54–56
The interactions of small molecules with IDPs challenge our understanding of
molecular recognition and it is important to clarify the mechanisms of IDP-small
molecule interaction before such proteins can be more routinely targeted. This
is here illustrated with a review of three well-studied systems: the oncoprotein
c-Myc, Aβ (amyloid β-peptide) and α-synuclein.








































Figure 2.9: The impact of ligand binding on the energy landscape of a globular
protein (A) and an intrinsically disordered protein (B).
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2.6.1 c-Myc
The proto-oncogene protein c-Myc consists of 439 amino acids and contains
an 88-amino-acid bHLHZip (basic helix-loop-helix leucine zipper) domain. In
its monomeric form, c-Myc is intrinsically disordered.57 c-Myc has been shown
to interact with a large number of other proteins. The specific interaction
between c-Myc and the protein Max has been studied extensively because the
c-Myc-Max heterodimer binds DNA and regulates gene expression.58 It has been
shown that overexpression of c-Myc is frequent in many cancers, and disruption
of the c-Myc-Max interaction is a possible anticancer strategy.41 Structurally
diverse small molecules inhibiting the formation of this complex were discovered
through a yeast two-hybrid screen.54 Biophysical studies using fluorescence assays,
nuclear magnetic resonance (NMR) and circular dichroism (CD) measurements
were performed to characterize protein-ligand interactions.57, 59, 60 These studies
suggest that the small molecules disrupt the c-Myc-Max interaction by stabilizing
conformations in monomeric c-Myc that are incompatible with heterodimerization
with Max. Three distinct binding sites, encompassing residues 366-375, 375-385
and 402-409, have been mapped on to the c-Myc bHLHZip domain.59 Remarkably,
the three distinct c-Myc-binding sites can be occupied simultaneously by different
ligands. These results suggest that the c-Myc-small molecule interactions are
fairly localized and can be predicted from primary sequence analysis. Indeed,
protein disorder prediction algorithms can locate approximately the small molecule-
binding sites of c-Myc, which tend to be enriched in hydrophobic amino acids
in comparison with the rest of the domain.57 In addition, many of the small-
molecule ligands can bind truncated c-Myc segments containing a single binding
site with a binding affinity similar to that of the full c-Myc bHLHPZip domain.
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Figure 2.10: Summary of the main interactions observed in three IDP-ligand com-
plexes: c-Myc-10058-F4, α-synuclein-dopamine and Aβ-Pep1b. The amino acids are
represented using the one-letter-code.
For instance, the small molecule 10058-F4 binds in a fluorescence polarization
assay to c-Myc353-437 with a Kd of 5.3±0.7 µM and to c-Myc402-412 with
a Kd of 13.3±1 µM.57 Furthermore, similar chemical shift perturbations were
observed for c-Myc353-437 and c-Myc402-412 upon binding 10058-F4. NMR
and CD studies suggest that c-Myc remains disordered upon binding 10058-F4.
Ligand binding appears to lead to formation of a hydrophobic cluster between
the ligand and the side chains of Tyr402, Ile403, Leu404 and Val406 (Figure
2.10). Molecular dynamics studies detailed in chapter 3 reveal multiple distinct
binding modes for 10058-F4, with frequent stacking interactions with Tyr402 as
well as hydrogen-bonding interactions with the backbone of Tyr402, Val406 and
Lys412.61
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2.6.2 Amyloid β-peptide
Alzheimer′s disease is a neurodegenerative pathology characterized by the
formation of senile plaques in the brain.62 The aggregation of Aβ is known
to be one of the main components of those plaques and may be associated
with the pathogenesis of Alzheimer’s disease.63, 64 Aβ (36-43 amino acids) is
produced by the successive cleavage of the APP (amyloid precursor protein)
by the enzymes β-secretase and γ-secretase. Although the role of APP is not
completely characterized, it appears to be crucial for synapse formation and
function.65 The aggregation of Aβ, as well as with other compounds such as
apoliprotein E, induces the development of senile plaques. Aβ adopts a folded
helical structure in membrane environments, but an aggregation-prone β-sheet
conformation in aqueous solution.66 Over the last few decades, many peptide
and small molecule inhibitors of Aβ aggregation have been discovered, primarily
through in vitro assays.67 Current small molecule inhibitors appear to inhibit Aβ
aggregation through at least two distinct mechanisms. For instance, scylloinositol
derivatives have been shown by electron microscopy experiments to bind and
stabilize monomeric and trimeric forms, thus blocking aggregation.68, 69 On the
other hand, compounds such as Thioflavin T or Congo Red appear to interact with
Aβ aggregates, although decades of studies on these compounds have produced
several conflicting models of binding mechanisms. Plausible hypotheses have
been recently reviewed extensively by Groenning.70 Computational studies have
attempted to clarify protein-ligand interactions. Molecular dynamics simulations
were performed recently for ten small-molecule inhibitors in the presence of a
truncated form of Aβ (Aβ12-28).71 Although the small molecules did not exhibit a
predominant binding mode and did not dramatically affect the secondary-structure
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preferences of Aβ12-28, a number of conserved interactions with Aβ12-28 could be
observed. Most of the ligands interacted preferentially with the N-terminal portion
of the peptide (residues 13-20). Energetic analysis revealed favourable electrostatic
interactions with three amino acids (His13, His14 and Lys16). Additionally,
favourable hydrophobic interactions are observed between the inhibitors and
the entire N-terminal stretch, with the sites of highest interaction probability
being near the side chains of Phe19 and Phe20. The binding affinities appear to
be roughly correlated with the number of aromatic groups and charged groups
present in the ligands. Molecular dynamics simulations have also been performed
to examine the interactions of two small ligands, Pep1b and Dec-DETA, that were
designed to stabilize the central helix in Aβ.72 Both ligands appear to stabilize
the Aβ central helix (residues 15-24) in Aβ13-26 by interacting preferentially with
two charged amino acids: Glu22 andAsp23. In addition, electrostatic interactions
with His13 and Lys16 as well as hydrophobic interactions with Phe19 and Phe20
were also reported for Pep1b (Figure 2.10). It appears that the extended side-
chain interactions between the ligands and Aβ disfavour intramolecular side-chain
interactions that would destabilize the central α-helix. Recently, molecular
dynamics simulations were used to study the interactions of inositol ligands with
(Gly-Ala)4 modelled either as disordered or β-sheet aggregates of four peptides,
or as an extended fibril-like oligomer.73 The ligands were observed to form
predominantly one or two hydrogen bonds with the peptide backbone. The results
suggested that inositol does not inhibit amyloid formation by dispersing preformed
aggregates or by preventing aggregation, but is more likely to bind instead to the
surface of prefibrillar aggregates.73 The computed dissociation constants of the
ligands were two orders of magnitude higher than those measured experimentally,
suggesting that additional sidechain interactions must contribute significantly to
the binding affinity of the inositol ligands to Aβ aggregates.73
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2.6.3 α-synuclein
The 140-amino-acid protein α-synuclein consists of three distinct domains.
The central region of α-synuclein is known to be crucial for the aggregation
of α-synuclein fibrils, one of the main components of Lewy bodies associated
with many neurodegenerative diseases such as Parkinson’s disease.74, 75 Under
physiological conditions, α-synuclein normally adopts a helical conformation that
is non-pathogenic and plays a role in neurotransmitter release. It is still not
well understood how α-synuclein first forms soluble oligomers called protofibrils,
followed by the development of β-sheet-rich α-synuclein fibrils. In light of these
observations, a deeper molecular-level understanding of interactions between
monomeric, protofibril and fibril forms is important to facilitate the discovery
of small molecule inhibitors of α-synuclein fibrillization. A few years ago, 15
fibrillization inhibitors were found by screening a small-molecule library using a
fibrillization assay.76 Many of these inhibitors are members of the catecholamine
family and include dopamine. There is controversy about the mechanisms of
interactions between dopamine and α-synuclein. Conway et al. have suggested that
dopamine readily oxidizes into dopamine-derived orthoquinones that subsequently
form a covalent adduct with α-synuclein by radical coupling to form dityrosine
linkages or by nucleophilic attack of a lysine side chain.76 On the other hand,
Norris et al. failed to detect significant levels of dopamine-α-synuclein adducts
and suggested instead that binding occurs through non-covalent interactions
with the α-synuclein segment Tyr125-Glu-Met-Pro-Ser129.77 Herrera et al. used
docking calculations and molecular dynamics simulations to study the interactions
of dopamine and several plausible oxidized derivatives with an NMR-derived
structural ensemble of α-synuclein.78 In the majority of the simulated complexes,
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the ligands interacted through a broad range of hydrogen-bonding and hydrophobic
interactions with the region Tyr125-Glu-Met-Pro-Ser129. Additionally, significant
electrostatic interactions were computed between the ligands and Glu83 located
in the non-β-amyloid region of α-synuclein. These predictions were tested by
a series of biophysical experiments. Point mutations to alanine in the Tyr125-
Glu-Met-Pro-Ser129 region did not prevent dopamine inhibition of α-synuclein
aggregation in an in vitro fibrillization assay, suggesting that dopamine interacts
nonspecifically with this region. On the other hand, mutation of Glu83 to alanine
strongly impaired the ability of dopamine to inhibit α-synuclein aggregation.78
Non-catecholamine inhibitors of α-synuclein aggregation have also been identified.
A broad range of biophysical methods were used by Lendel et al. to characterize
the interactions of Congo Red and lacmoid with α-synuclein.79 They concluded
that these two small molecules interact broadly with the N-terminal and central
region of α-synuclein as small oligomeric species.79
2.6.4 Conclusion
Although small molecules have now been found to interact directly with
several IDPs in their monomeric form, an important challenge is to clarify the
specificity of the interactions. For instance, there are numerous proteins that
contain a bHLHZip domain similar to that of c-Myc. Consequently, several small
molecules that inhibit the c-Myc-Max complex also inhibit related bHLHZip
pairs. To illustrate, the compound 10058-F4 has also been shown in a yeast
two-hybrid assay to disrupt the complexes MyoD- E2-2, Mad1-Max and Mxi1-
Max, although several other bHLHZip pairs were not inhibited.54 Several of the
dopamine derivatives that inhibit α-synuclein aggregation have also been shown
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to also dissolve fibrils of Aβ in vitro.80 Congo Red and lacmoid bind readily to α-
synuclein, a protein closely related to α-synuclein which does not aggregate under
physiological conditions.79 In several cases, relatively structurally diverse small
molecules have been found to interact with similar regions in an IDP. Additionally,
many studies suggest that the complexes between small molecules and IDPs
remain disordered.81 This suggests that the binding of the small molecules is
driven by a large number of weak interactions.46 Arguably, unlike proteins, small
molecules are unlikely to induce IDP folding upon binding, as the relatively
limited intermolecular contacts that they form are unlikely to overcome the
large conformational entropy loss necessary to structure an IDP. Structure-based
approaches to design ligands for IDPs will therefore have to explicitly consider
multiple binding modes. Although the mechanisms of IDP aggregation are still not
well understood, a number of small-molecule inhibitors of IDP aggregation have
reached clinical studies. For instance, methylthionium chloride, initially developed
as an antimalarial agent, has been shown to inhibit in vitro the aggregation of
the IDP tau.82 Results of a Phase II clinical trial reported that methylthionium
chloride slows down cognitive impairment in patients suffering from Alzheimer’s
disease, thus inhibiting the formation of tau aggregates is a promising strategy
for the development of Alzheimer’s disease treatments.83
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An Example of IDPs : c-Myc
This chapter describes the impact of small molecule binding on the energy landscape
of c-Myc
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In the introduction chapter, it has been explained that a key requirement of
structure-based drug design approaches is the availability of the three dimensional
structure of a protein target. However, in solution, a protein cannot be considered
as a rigid entity, rather it oscillates between different conformations with similar
free energy.1 Furthermore, a majority of proteins involved in diseases such as
cardiovascular and neurodegenerative pathologies or cancers are known to be
very flexible and the study of such proteins so called Intrinsically Disordered
Proteins (IDPs) remains very challenging.2 In this chapter, several computational
methodologies were used to investigate the formation of ‘hidden pockets’ at the
protein surface of the oncoprotein c-Myc and to study the impact of small molecule
binding on the free energy landscape of this transcription factor.3
3.1 The oncoprotein c-Myc
c-Myc and the other proteins of the Myc family were among the first proto-
oncogenes to have been identified.4 These proteins are transcription factors able
to activate the expression of several genes regulating many processes such as cell
proliferation, cell differentiation or apoptosis. c-Myc, as other proteins belonging
to this family, is organized into three different domains:5
1. A region for transcription activity in its N-terminal portion containing two
highly conserved domain elements: MYC Box I (residues 45-63) and MYC
Box II (residues 129-143) that are essential for the transactivation of the
target genes.
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2. A central region containing a nuclear localization site (residues 320-328), as
well as two others MYC Box recently identified: MBIII (residues 188-199),
which plays a role in cell transformation and MBIV (residues 295-315),
involved in DNA binding, apoptosis, transformation and cell cycle arrest in
G2.6, 7
3. A C-terminal domain, consisting of a basic region (residues 354-367) involved
in recognition and binding to specific DNA sequences; a Helix-Loop-Helix
domain (residues 368 to 407) and a Zip or Leucine Zipper motif (residues
413-434). This third region is illustrated in Figure 3.1A.
In its monomeric form, c-Myc is intrinsically disordered.8 c-Myc has been
shown to interact with a large number of other proteins. The specific interaction
between c-Myc and the protein Max has been studied extensively because the
c-Myc-Max heterodimer binds DNA and regulates gene expression.9 It has been
shown that overexpression of c-Myc is frequent in many cancers, and disruption
of the c-Myc-Max interaction is a possible anticancer strategy.10 Structurally
diverse small molecules inhibiting the formation of this complex were discovered
through a yeast two-hybrid screen.11 Biophysical studies using fluorescence assays,
Nuclear Magnetic Resonance (NMR) and Circular Dichroism (CD) measurements
were performed to characterize protein-ligand interactions.8, 12, 13 These studies
suggest that the small molecules disrupt the c-Myc-Max interaction by stabilizing
conformations in monomeric c-Myc that are incompatible with heterodimerization
with Max. Three distinct binding sites, encompassing residues 366-375, 375-385
and 402-409, have been mapped on to the c-Myc bHLHZip domain.12 Remarkably,
the three distinct c-Myc-binding sites can be occupied simultaneously by different
ligands. These results suggest that the c-Myc/small molecule interactions are
fairly localized and can be predicted from primary sequence analysis. Indeed,
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protein disorder prediction algorithms can locate approximately the small molecule-
binding sites of c-Myc, which tend to be enriched in hydrophobic amino acids
in comparison with the rest of the domain.8 In addition, many of the small-
molecule ligands can bind truncated c-Myc segments containing a single binding
site with a binding affinity similar to that of the full c-Myc bHLHPZip domain.
For instance, the small molecule 10058-F4 binds in a fluorescence polarization
assay to c-Myc353-437 with a Kd of 5.3±0.7 µM and to c-Myc402-412 with a Kd of
13.3±1 µM.8 Furthermore, similar chemical shift perturbations were observed for
c-Myc353-437 and c-Myc402-412 upon binding 10058-F4. Therefore the small peptide
c-Myc402-412 appears to be a good model to study the interactions of 10058-F4
with full lenght c-Myc.
To detect and characterize hidden binding sites, MD simulations prove to
be an attractive choice. In order to study the impact of small molecule binding
on the energy landscape of the truncated peptide c-Myc402-412, bias-exchange
metadynamics simulations (BEMD) were performed in explicit solvent in absence
and in presence of 10058-F4.14
3.2 Materials & Methods
3.2.1 Metadynamics Simulations
The protein and the ligand were built and prepared using the software
Maestro.15 The peptide termini were acetylated and amidated to be coherent with
experimental data. All simulations were performed with the suite GROMACS
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Figure 3.1: A) Structure of c-Myc (red) in complex with Max (blue) interacting with
DNA (PDB code: 1NKP). The bHLHZip domain is formed by two helices separated by a
small loop. According to the literature, the part of c-Myc targeted by the small molecule
10058-F4 (insert) is highlighted in green (sequence: YILSVQAEEQK). B) Chemical
structure of the amino acid sequence used for the molecular dynamics simulations. The
Cα, Cβ and Cγ are respectively represented in red, blue and green.
92 3. An Example of IDPs : c-Myc
4.5.5 compiled with the plugin PLUMED 1.3.16, 17 The AMBER99SB* forcefield
was selected for the small peptide c-Myc402-412 while the GAFF force field was used
for 10058-F4.18, 19 The GAFF parameters for the ligand were obtained by using
the python script ACPYPE in combination with the antechamber utility from the
AMBER 11 software package.20, 21 Atomic partial charges were assigned using the
AM1-BCC method.22, 23 Both systems apo c-Myc402-412 and c-Myc402-412/10058-F4
were solvated in a triclinic box with respectively 2843 and 3211 TIP3P water
molecules and filled with enough counter ions to keep the system neutral. The
minimal distance of the peptide to the boundary of the simulation box was at least
1.0 nm.24 Temperature was controlled by a stochastic Berendsen thermostat and a
coupling time of 0.1 ps. The default temperature for all simulations was 300 K. The
pressure was controlled using a Parrinello-Rahman barostat at constant pressure
1 atm with a coupling time of 2.0 ps.25 Long range electrostatic interactions
were treated both with a short-range cut-off of 0.9 nm and the Particle-mesh
Ewald method. A similar cut-off was used for the Lennard-Jones interactions. The
neighbor list was updated every 10 integration steps. A long-range correction term
was used for the energy and pressure.26After NPT equilibration, all production
runs were performed for 120 ns in NVT conditions using a time step of 2.0 fs and
LINCS constraints were applied to all covalent bonds.27
Preliminary runs were performed to optimize both the selection and the
parametrization of CVs. The choice of those collective variables (CVs) were
influenced by previously published BEMD studies to overcome possible energetic
barriers between different peptide conformations.28, 29 The parameters of the CVs
(Gaussian height and width), which control the rate of convergence and accuracy
of the free energy profiles were adjusted in preliminary runs in implicit solvent so
as to obtain reasonably converged free energy profiles on a timescale of several
dozen nanoseconds. Gaussian potentials of height 0.2 kJ.mol-1 were added every
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2.0 ps. Collective variables and snapshots were saved every 2.0 ps and exchanges
between replicas were attempted every 20.0 ps.
The simulations in presence (holo) and in absence (apo) of the ligand were
performed with 8 and 9 replicas respectively. Each simulation was repeated twice
using two different sets of starting conformations. These starting coordinates were
obtained from preliminary runs and it was checked that they were structurally
diverse and uncorrelated. Thus a total of 4 BEMD simulations were performed:
two apo simulations (apoA and apoB) and two holo simulations (holoA and holoB)
using three different CVs.17



















m if rij > 0
(3.2)
where rij = ‖ri−rj‖−d0. The parameters r0, d0, n andm were adjusted according
to the type of interaction.
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where β=50.0










where i is a hydrogen bond donor, j is a hydrogen bond acceptor and dij is the
distance between between the atoms i and j.





2 (1 + cos (φi − φi−1)) (3.5)
where ND is the number of dihedrals in the CV.












The parameters of each CV used to bias apo and holo simulations are given
hereafter:
• Apo simulations: CV1: coordination number Cα atoms (n = 8,m =
10, r0 = 0.65 nm, d0 = 0.0 nm), width 0.7; CV2: coordination number Cγ
atoms (n = 8,m = 10, r0 = 0.5 nm, d0 = 0.0 nm), width 0.5; CV3, similarity
of backbone dihedral Ψ angle to α-helical region (φi = −1.31), width 0.25;
CV4, correlation of successive backbone dihedral angles; CV5: number of
backbone - backbone hydrogen bonds (r0 = 0.25 nm), width 0.25; CV6:
number of sidechain - sidechain hydrogen bonds (r0 = 0.25 nm), width
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0.25; CV7: number of sidechain - backbone hydrogen bonds (r0 = 0.25 nm),
width 0.25;
• Holo simulations: Holo simulations: CV1: coordination number Cα atoms
(n = 8,m = 10, r0 = 0.65 nm, d0 = 0.0 nm), width 0.7; CV2: coordination
number Cγ atoms (n = 8,m = 10, r0 = 0.5 nm, d0 = 0.0 nm), width 0.5;
CV3, similarity of backbone dihedral Ψ angle to α-helical region (φi =
−1.31), width 0.25; CV4, correlation of successive backbone dihedral angles;
CV5: number of backbone - backbone hydrogen bonds (r0 = 0.25 nm),
width 0.25; CV6: number of sidechain - sidechain hydrogen bonds (r0 =
0.25 nm), width 0.25; CV7: number of sidechain - backbone hydrogen bonds
(r0 = 0.25 nm), width 0.25; CV8: minimum distance ligand C1 atom to
peptide Cα atoms. C1 is the aromatic carbon atom bonded to the methylene
group of 10058-F4.
The gaussian accumulation allows the system to escape from a local minima
and to gradually explore a broad range of values along each CV. This trend is
more pronounced for CVs defined by counting interatomic contacts and eventually
leads to the sampling of high energy configurations that cause hysteresis in the
convergence of the free energy profiles for the biased replicas. However these
limitations are significantly reduced by exchanging conformations between different
runs according to the metropolis criterion. Moreover, high-energy configurations
are almost never transferred to other replicas during replica exchange tests. To
maintain a reasonable exchange rate between replicas and to focus conformational
sampling in the regions of low free energy, half-harmonic potentials (walls) were
added to penalize exploration of CV values below or above minimum/maximum
values such that the computed free energy profiles are within approximately 10
kBT from the global minimum. The position of the walls was chosen by performing
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unrestrained preliminary BEMD runs.
• Walls: CV1: minimum 57, maximum 96; CV2: minimum 36, maximum 63;
CV3: minimum 1, maximum 9; CV4, minimum 1.5, maximum 9.9; CV5,
minimum 0.50, maximum 10.50; CV6, minimum 0.40, maximum 9.00; CV7
minimum 1.25, maximum 10.25; CV8 minimum 0.33, maximum 0.97.
With this setup the average exchange probability between biased replicas and
neutral replicas was about 33% for both apo and holo simulations. According to
the observed fluctuations in the values of the CVs over the duration of the BEMD
simulations, all simulations have converged after 20 ns . Only the remaining 100
ns were considered for the analysis. The free energy profiles shown in Figure
3.2 and Figure 3.3 were taken as the negative of the averaged metadynamics
biasing potential over the last 100 ns of each simulations. Computing equilibrium
properties from low dimensional free energy projections is not an easy task.
Indeed, when one wants to study a convoluted process such as the impact of
ligand binding on the conformational sampling of a protein, each minimum in
a low dimensional profile may correspond to several different structures. To
overcome this limitation, the method of Marinelli et al. was used to reweigh
snapshots from the biased simulations.30 In this technique, the biased trajectories
are first clustered in a N-dimensional CV space made of hypercubes forming
a regular grid. The free energy of each bin is then estimated by a weighted
histogram analysis procedure (WHAM) based on the number of snapshots and
the value of the converged metadynamics bias potentials assigned to each bin
(see Introduction for more details). As described by the authors, the accuracy
of this approach is highly dependent of the bin properties. First, bins have to
cover all the configuration space explored along the CV. Then, a large number
of bins must be used and also be populated by a significant number of similar
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conformations. After investigation using the VMD plugin METAGUI,31 the
best parameters identified for c-Myc402-412 involved a 4-dimensional clustering
using CV1, CV3, CV4, CV5 with a bin width of approximately 2σi, where σi
is the Gaussian width of CVi.31, 32 The choice of those 4 CVs were based on
their poor correlation with each other, thus maximizing structural similarity of
snapshots assigned to each bin. The bin width of 2σi is on the order of the
resolution of the metadynamics free energy profiles. With this setup about 9000
bins were defined containing at least 5 snapshots. Lower dimensionality clustering
produced bins that lumped together structurally dissimilar states, whereas higher
dimensionality clustering yielded very few bins populated with more than five
snapshots. Molecular observables were averaged between snapshots assigned to
the same bin. Ensemble properties were then obtained by weighting the properties
of each bin by its WHAM derived free energy. Concerning the ensemble properties
of the neutral replica, they were simply computed by averaging the properties
of each snapshot of the simulation. Beside the BEMD simulations, two classical
MD simulations of c-Myc402-412 were also performed (mdA and mdB). Similar
simulations parameters to BEMD simulations were used but the time step that
was set to 5 fs as virtual sites were used, and the simulations duration was 110
ns.33 The first 10 ns were discarded to enable relaxation of the system. Thus,
only the last 100 ns were considered for the analysis.
3.2.2 Simulations Analysis
In order to evaluate the equilibrium ensembles of c-Myc402-412, the software
Camshift was used to predict several NMR chemical shifts (1H, 1Hα, 13Cα and
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13Cβ).34 Camshift predictions are based on a polynomial expansion of the inter-
atomic distances of the protein conformation. Because the approach is not able to
assess the chemical shifts for N and C terminal residues no results are shown for
Tyr402 and Lys412. DSSP, STRIDE and PROSS were used to assess the secondary
structure preferences from the simulations while the webserver δ2D was used to
predict the same properties from the measured chemical shift.35–39 A contact
matrix was built to determine the preferred intramolecular and intermolecular
interactions of c-Myc402-412 in the apo and holo ensembles. A cutoff of 3 Å was
used to define a proton-proton contact, which is intermediate between distances
compatible with strong/medium NOEs. Small variations in this cutoff (±0.5Å)
did not affect significantly the results. The approach developed by Daura et al.
was applied to highlight the main conformations of the apo and holo equilibrium
ensembles and estimates their proportion.40 This iterative method relies on a
RMSD clustering. First, RMSD calculations were performed between all pairs
of structures in a trajectory. Then, for each snapshot, the number of structures
that have a RMSD below a cutoff value are counted. The conformation with the
highest number of similar structures is selected to define a cluster centre. This
structure, along with all neighboring structures, is removed from the trajectory.
Finally, the process is repeated until every structures are assigned to a cluster.
In order to speed up the process while minimizing impact on the accuracy of
the results, only snapshots from bins that were within 6kBT from the bin of
lowest free energy were selected. To estimate errors on the cluster populations,
the ensembles from the two apo/holo simulations were combined using a RMSD
cutoff of 3.5 Å. Different groups of atoms were retained to perform the RMSD
calculations for the apo and holo ensembles.
For the apo simulations, all heavy atoms not involved in symmetry equivalent
conformations (e.g Valine Cγ atom) were selected. Another selection is required
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to consider the different possible binding modes of the ligand. The RMSD
calculations were performed on the protein Cα and Cβ atoms and non-symmetry
equivalent ligand heavy atoms. Thus, the ligand coordinates were weighted by a
factor of 3 in the RMSD calculations to in order to cluster together conformations
that contained similar ligand coordinates.
3.3 Results
In order to characterize the structural ensembles of the peptide c-Myc402-412
and the complex c-Myc402-412/10058-F4 the bias-exchange variant of metadynamics
was used.14 Several biased simulations were run in parallel allowing a rapid
exploration of the energy landscape of the system along a set of predefined
collective variables. The technique is presented in detail in the Introduction
chapter. Beside the biased simulations, an additional run without any bias,
so called neutral replica, was able to exchange conformations with the other
trajectories. According to the literature, the neutral replica has been found to
produce an ensemble similar to the equilibrium ensemble of the system.14, 30, 41, 42
Thus, BEMD has been shown to be an attractive tool to enhance the sampling of
the folding free energy landscape of small proteins and protein/ligand complexes
on timescales of a few dozen ns.41, 43
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3.3.1 Conformational sampling of c-Myc402-412
To ensure that the simulations have converged, one dimensional free energy
profiles along the CVs used to enhance conformational sampling were computed.
The reconstruction is obtained using the negative of the sum of the Gaussian
biases added along the CV during the simulation.44 These calculations were
performed on two independent set of apo and holo simulations starting from
structurally unrelated conformations. This was done to verify the reproducibility
of our simulations.
The results are shown in Figures 3.2 & 3.3. In general the free energy
profiles within 10 kJ.mol-1 of the global minimum are well reproduced (within
ca. 1 kBT or less) for most CVs between the two independent simulations. In
the apo simulations, only the CV2 (coordination number Cγ atoms) shows a
few discrepancies between the two simulations. The largest gap (5 kJ.mol-1)
was observed in the range of CV values of 40-50 contacts. Concerning the holo
simulations, the biggest differences are more located in the regions of high free
energy for CV2, CV3, CV4 and CV5 (Figure 3.3 B-E). In those regions, the
divergence can reach 10 kJ.mol-1. However, protein conformations with a high
free energy contribute marginally to the equilibrium ensemble. Thus, the overall
equilibrium properties back-computed from the biased simulations remain actually
similar (e.g. Table 3.1 and Figure 3.5). As suggested by the Figure 3.4 A, the
visual inspection of the apo neutral replica ensemble has confirmed that the
system can adopt a broad range of conformations from compact to fully extended
presenting occasionally secondary structure elements. The BEMD neutral replica
ensembles were compared to two 100 ns unbiased MD simulation performed using
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Figure 3.2: Free energy profiles for the c-Myc402-412 apo simulations projected along
several collective variables. Black: Simulation apoA, Red: Simulation apoB.A) CV1:
coordination number Cα atoms. B)CV2: coordination number Cγ atoms. C) CV3:
similarity of backbone dihedral Ψ angle to α-helical region. D) CV4: correlation
of successive backbone dihedral angles. E) CV5: number of backbone - backbone
hydrogen bonds. F) CV6: number of sidechain - sidechain hydrogen bonds. G) CV7:
number of sidechain - backbone hydrogen bonds.
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Figure 3.3: Free energy profiles for the c-Myc402-412 holo simulations projected along
several collective variables. Black: Simulation holoA, Red: Simulation holoB.A) CV1:
coordination number Cα atoms. B) CV2: coordination number Cγ atoms, width 0.5;
CV3, similarity of backbone dihedral Ψ angle to α-helical region. C) CV4: correlation
of successive backbone dihedral angles. D) CV5: number of backbone - backbone
hydrogen bonds. E) CV6: number of sidechain - sidechain hydrogen bonds. F) CV7:
number of sidechain - backbone hydrogen bonds. G) CV8: minimum distance ligand
C1 atom to peptide Cα atoms.
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Figure 3.4: Secondary structure content of c-Myc402-412. Residue secondary structure
preferences colored according to the STRIDE code (white: coil, cyan: turn, blue: 310
helix, purple: α-helix, maroon: bend, yellow: extended). A) and B) BEMD ensembles
from the neutral replicas for simulations apoA and apoB. C) and D) Unbiased ensembles
from MD simulations mdA and mdB.
the same potential energy function and system setup. The first MD simulation
was initiated from an extended conformation which quickly forms a short α-helix
from the amino acid Leu404 to Ala408 that is stable throughout the simulation
(Figure 3.4 C). A very different conformational ensemble is observed for the second
classical MD simulation (Figure 3.4 D). The system adopts mainly unstructured
conformations. The lack of consistency between those two unbiased trajectories is
a good illustration of the limitation of MD simulations to sample conformations
from different local minimum compared to BEMD.
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Figure 3.5: Comparison of computed and observed secondary chemical shifts for apo
c-Myc402-412. A) 1Hα chemical shifts. B) 13Cα chemical shifts. C) 1H backbone amide
chemical shifts. D) 13Cβ chemical shifts. Black: experimental data. Solid red and blue:
predicted by reweighting the biased BEMD simulations apoA and apoB respectively.
Dotted red and blue: predicted from the neutral replicas of the BEMD simulations
apoA and apoB respectively. Not all experimental 13Cβ chemical shifts were reported.
Camshift does not report chemical shifts for terminal residues.
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Helix Sheet Polyproline
BEMD run1A 13.9 10.0 0.7 0.9 12.6
BEMD run2A 10.9 9.4 0.6 0.2 12.1
BEMD run1 neutralA 14.2 11.9 0.7 1.0 11.6
BEMD run1 neutralA 10.5 9.2 0.5 0.2 11.7
MD run1A 34.3 41.5 0.0 0.0 5.5
MD run1A 0.1 0.1 0.5 0.5 13.5
ExpB 4.0 3.0 13.0
Table 3.1: Percentage of secondary structure content of apo c-Myc402-412.Ahelix and
sheet content were computed using the software DSSP and STRIDE respectively. A
helix was defined as G + H + I according to the DSSP code. The polyproline II content
was calculated with the software PROSS.BStructural features of the experimental data
were estimated from the chemical shifts using the webserver δ2d.
To evaluate the accuracy of the equilibrium ensemble generated from the
simulations, snapshots collected during the apo MD and BEMD simulations of
c-Myc402-412 were used to back-compute NMR chemical shifts using the software
Camshift.34 Subsequently, 1H and 13C secondary chemical shifts for Hα protons,
backbone amide protons, Cα and Cβ carbons were compared with experimental
data (Figure 3.5).13 Unfortunately, comparison of computed and measured
chemical shifts for the c-Myc402-412/10058-F4 complex is not possible owing to the
lack of parameters in Camshift to describe the ligand. The secondary chemical
shifts generated from the two BEMD ensembles show a good correlation with
experimental values. Furthermore, only very small differences are observed
between the chemical shifts obtained by averaging over snapshots from the
neutral replicas or by reweighting snapshots from the biased simulations. By
contrast, greater variability and inconsistency is observed between the chemical
shifts computed from the two unbiased MD simulations (Figure 3.6). The mean-
unsigned errors for the Hα, H, Cα and Cβ chemical shifts computed from the two
reweighted BEMD simulations are: 0.09/0.08, 0.43/0.44, 0.32/0.28 and 0.35/0.32
ppm respectively. Similar values were observed for the mean-unsigned errors
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computed for the neutral replica ensembles: 0.09/0.08, 0.45/0.46, 0.32/0.29 and
0.34/0.35 ppm respectively. By comparison the mean-unsigned errors computed
from the two MD simulations are: 0.15/0.13, 1.25/0.80, 0.50/0.42, 1.01/0.86
ppm respectively. As shown previously, the back-computed secondary chemical
shifts suggest also that the protocol using BEMD produced more accurate and
consistent equilibrium ensembles between independent runs. A last analysis was
performed comparing the secondary structure content generated from our different
equilibrium ensembles with experimental data (Table 3.1). The webserver δ2d was
used to estimate the percentage of helix and sheet from the experimental chemical
shifts.39 The polyproline II content was calculated with the software PROSS.38
The overall secondary structure content of the BEMD and MD ensembles was
calculated using the softwares DSSP and STRIDE.35–37 As shown in Table 3.1,
both MD and BEMD are quite insensitive to the methodology used to predict
the secondary structure. In general, the polyproline II, helix and sheet content
of the BEMD simulations computed from the reweighted and the neutral replica
ensembles was very similar and consistent. However, compared to experimental
results, the proportion of helix was globally overestimated while the sheet content
was underestimated. This systematic error could have been driven by the force
field selected for the simulations. The most significant differences are seen in the
MD simulations. In the first run helical conformations are mainly predicted. By
contrast, only the polyproline II content matches experimental data. Given that
both BEMD and MD simulations have been performed under similar conditions,
the differences observed for the MD simulations could be explained by larger
sampling errors. Although it is likely that optimized force fields could decrease
further discrepancies with experiment, the computed BEMD ensemble is overall
in reasonable agreement with the available experimental data for this system.
Along the different analysis completed on the BEMD simulations of c-
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Figure 3.6: Comparison of computed and observed secondary chemical shifts for
apo c-Myc402-412 for the amino acids 403 to 411. A) 1Hα chemical shifts. B) 13Cα
chemical shifts. C) 1H backbone amide chemical shifts. D) 13Cβ chemical shifts. Black:
experimental data. Red: predicted from MD simulation mdA. Blue: predicted from
MD simulation mdB.
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Myc402-412, the results generated from the neutral replica was always very similar to
the properties predicted by reweighting the biased simulations. This observation,
in agreement with other bias- exchange metadynamics studies, suggests that
the neutral replica is a good approximation of the equilibrium ensemble. As
shown in Figure 3.7, the global minimum of the one-dimensional free energy
profiles of all CVs are well reproduced. By contrast, the regions of high free
energy are systematically overrepresented in the neutral replica. However, because
conformations present in these CV values contributes marginally to the equilibrium
ensemble, this does not affect significantly the different equilibrium properties
(Figure 3.5 and Table 3.1 ). Nevertheless this analysis suggests that the accuracy
of the neutral replica ensemble decreases rapidly for conformations of higher free
energy. Consequently, analyses in the rest of the chapter were performed on
ensembles constructed by reweighting snapshots from the biased simulations.
3.3.2 The c-Myc402-412 Apo Ensemble
Clustering of the apo equilibrium ensemble of c-Myc402-412 reveals dozen of
structurally distinct conformations from collapsed to extended. Such heteroge-
neous sampling was predictable considering the intrinsically disordered feature of
this system. Figure 3.8 depicts representative conformations from the nine largest
clusters calculated for the apo ensemble. Similar clusters were found in the two
independent simulations but sometimes not equally populated. The main cluster
(Figure 3.8 A) is a random coil structure stabilized by hydrophobic contacts
between Tyr402, Ile403 and Val406 and electrostatic interactions between Lys412
and Glu409. Other partially collapsed conformations are represented (Figures 3.8
D & 3.8 E) as well as extended conformations are also observed (e.g Figure 5F
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Figure 3.7: Comparison of free energy profiles of c-Myc402-412 obtained from the
neutral replica and the biased replicas. Black: Neutral replica, Red: Biased replica.
Data generated using BEMD simulation apoA.
and 5I). Additionally, several clusters include conformations containing short α or
310 helices (Figures 3.8 B & 3.8 G), that account for the overall computed helical
content of c-Myc402-412.
3.3.3 c-Myc402-412 Remains Disordered upon Binding the Small Molecule 10058-F4
In order to assess the impact of the binding of 10058-F4 on the conformations
of c-Myc402-412, the average number of contacts between protons in 10058-F4 and
different protein residues was computed for the apo and holo BEMD simulations.
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Figure 3.8: Representative conformations from the computed equilibrium ensemble
for apo c-Myc402-412. The conformations depicted are those closest to the center of
the most populated clusters. The fractional cluster populations are: 0.101±0.018 (A),
0.075±0.034 (B), 0.060±0.040 (C), 0.059±0.027 (D), 0.055±0.016 (E), 0.043±0.004
(F), 0.030±0.017 (G), 0.021±0.009 (H), 0.021±0.003 (I).
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Results using a cut-off of 3 Å are shown in Figure 3.9. The upper panel (Figure 3.9
A) suggests that 10058-F4 binds preferentially the N-terminal region of c-Myc402-412
and more specifically Tyr402. In the C-terminal region, only interactions with
Lys412 are visible. Given that 10058-F4 contains a moderately polar heterocycle
and a hydrophobic ethylphenyl group, it is not surprising that intermolecular
contacts occur preferentially with the N-terminal region as it is enriched in
hydrophobic amino acids. Figure 3.9 B depicts the difference in average number
of contacts between protein residues in the apo and holo simulations. A decrease
of contacts between Tyr402 and the neighboring amino acids is consistent with
the previous results suggesting preferential interactions between 10058-F4 and
the end of the N-terminal region. An increase in contacts between Lys412 and the
N-terminal part is clearly correlated with a decline number of interactions with
the C-terminal domain. Those differences are explained by the observation that in
the holo simulations, many conformations where c-Myc402-412 is wrapping 10058-
F4 are observed. Therefore, the terminal amino acids are more likely to be in
contact with each other when the ligand is present. Additionally, the simulations
suggest formation of a hydrophobic cluster between 10058-F4 and the side chains
of Tyr402, Ile403, Leu404, Val406, which is in consistent with the experimental
data published by Follis et al.8 However, the holo equilibrium ensemble remains
overall heterogeneous suggesting that 10058-F4 does not stabilize significantly
c-Myc402-412.
3.3.4 The Small Molecule 10058-F4 Binds Different c-Myc402-412 Conformations
A visual inspection of the holo simulations reveals an important mobility of
10058-F4 all around c-Myc402-412 involving a multitude of different binding modes.
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Figure 3.9: Average number of contacts between 1 and c-Myc402-412. A) Average
number of 1H contacts between different c-Myc402-412 residues and 1. Color coded
from white (no contacts) to red (high number of contacts). The extreme values of
this color scale range from 0.02 to 1.08. B) Difference in the average number of
1H contacts between different c-Myc402-412 residues in the holo and apo ensembles.
Red/blue indicates an increased/decreased average number of contacts upon binding
of 1. The extreme values of this color scale range from -1.22 to +0.67.
Consequently clustering analysis of the holo ensemble produces a large number of
negligibly populated clusters. However, the most important clusters suggest that
10058-F4 interacts preferentially with specific c-Myc402-412 conformations allowing
to define the more likely binding modes (Figure 3.10).
The largest cluster (Figure 3.10 A) depicts stacking interactions between the
phenyl rings of 10058-F4 and Tyr402, as well as hydrophobic contacts between the
ethylphenyl group of 10058-F4 and Leu404. Ile403 is involved in a small hydrophobic
cluster with Leu404 and Tyr402. The conformation is also stabilized by several
hydrogen-bonds between Gln411 and the c-Myc402-412 backbone. A different binding
mode is depicted in Figure 3.10 B. The ethylphenyl group of 10058-F4 is stacked
between the side-chains of Tyr402 and Lys412, while the thiazolidinone ring forms
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hydrogen bonding interactions with the backbone of Leu404 and Gln407. Other
hydrophobic interactions between 10058-F4 and c-Myc402-412 seem to stabilize
the peptide in a helical conformation as shown in Figure 3.10 D & I. Only few
contacts are observed for the four other clusters. Comparison of the computed
holo c-Myc402-412 conformations with the conformation of c-Myc402-412 observed in
the crystallographic structure of the c-Myc/Max dimer systematically indicates
steric clashes with Max. Consequently, binding of 10058-F4 to c-Myc is not
compatible with c-Myc/Max dimerization.
As discussed by Wang et al, the lack of well-defined structure of the c-
Myc402-412/10058-F4 complex could explain that just a few chemical modifications
of 10058-F4 are able to improve significantly its binding affinity.45 The largest
populated holo cluster shows some important structural divergences with the
c-Myc402-412/10058-F4 complex derived using chemical-shift constraints and dock-
ing.8 However, a single average structure generated from minimization of NMR
derived restraints may not be representative of the multiple distinct conformations
adopted by a disordered protein.8 Therefore, molecular dynamics simulation
is an attractive tool to generate structural ensembles for IDPs and guide the
interpretation of NMR measurements.
3.3.5 c-Myc402-412/10058-F4 Conformations are Partially Formed in the Apo Ensemble
In order to characterize the mechanisms of molecular recognition, the most
representative apo and holo c-Myc402-412 conformations (Figures 3.8 & 3.10) were
compared to the computed apo and holo ensembles. The backbone root mean
square deviation (RMSD) of the apo and holo structural ensembles according to
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Figure 3.10: Representative conformations from the computed equilibrium ensemble
for the c-Myc402-412/10058-F4 complex. The conformations depicted are those clos-
est to the cluster center. The fractional cluster populations are: 0.021±0.008 (A),
0.019±0.002 (B), 0.018±0.005 (C), 0.015±0.010 (D), 0.014±0.003 (E), 0.011±0.008
(F), 0.011±0.005 (G), 0.011±0.001 (H), 0.010±0.003 (I).
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relevant apo and holo conformations is presented in Figure 3.11. The backbone
RMSD cut-off to consider two protein structures as similar is never trivial to define,
and is also highly dependent of the size of the system. For c-Myc402-412, a backbone
RMSD below 2.5 Å or less identifies roughly similar backbone conformations.
Using this criterion, it was found that the c-Myc402-412 apo ensemble contains
backbone conformations that are structurally comparable to those seen more
frequently in the holo ensemble (Figures 3.11 A-C), albeit with a lower probability.
Figure 3.11 D highlights that frequently observed apo conformations are also
present in the holo ensembles. To illustrate, Figure 3.11 also depicts an overlay of
the conformation sampled from the apo (Figure 3.11A-C) or holo (Figure 3.11D)
ensemble that has the lowest RMSD to the apo/holo conformations depicted
in Figure 3.10A-C and Figure 3.8A. Even if these results suggest that there is
significant structural overlap between the backbone of the apo and holo structures,
side-chain rearrangements are necessary to allow apo c-Myc402-412 conformations
to accommodate 10058-F4.
3.4 Conclusion
Classical molecular dynamics and bias-exchange metadynamics simulations
were performed on the small peptide c-Myc402-412. The results add to the growing
list of publications highlighting the usefulness of BEMD simulations to enhance
conformational sampling of a protein.30, 39, 41–43 Nevertheless, they also point out
the difficulty of simulating the behaviour of IDPs using biomolecular force fields
and a water model that are not always well adapted to describe flexible proteins
with small energy differences between conformations interacting extensively with
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Figure 3.11: Comparison of selected holo and apo conformations to the apo and holo
ensembles. A) Probability distribution of backbone RMSD of conformations from the
apo (black curve) and holo (red curve) ensembles to: A) holo cluster center 3.10A, B)
holo cluster center 3.10B, C) holo cluster center 3.10C, D) apo cluster center 3.8A.
The inset shows the low-RMSD regions.Each panel also shows an overlay of the lowest
RMSD apo or holo structure to cluster centers from panels A-D. For clarity only the
peptide backbone (tube representation, apo conformations in blue, holo conformations
in orange) and the ligand atoms (CPK) are shown.
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the solvent. Therefore, comparing the equilibrium ensemble computed from the
trajectories with experimental data such as NMR chemical shift is crucial to
validate the simulations.39 The systematic larger errors in predicted secondary
structure content and chemical shifts for the MD simulation versus the BEMD
simulations described along this chapter illustrate the consequences of a poor or
insufficient conformational sampling for at least the regions of low free energy.46
The CVs used in this study have generated a broad range of conformations in
both apo and holo equilibrium ensembles of c-Myc402-412. As it has been suggested
by Marinelli et al., that constructing a kinetic model of a system offers a better
understanding of the free energy landscape.30 Even if the kinetic properties are
not directly available from the BEMD simulations, it is possible to project the
BEMD trajectories on a space defined by the collective variables to build a kinetic
model. However, the large heterogeneity of the structural ensemble of c-Myc402-412
did not allow to clearly distinguish different kinetic basins in a low dimensional
CV space. An interesting alternative would be to conduct extended unbiased
MD simulations to reversibly simulate binding/unbinding in this system and
analyze the computed trajectories using Markov State models.47, 48 Furthermore,
it has been shown that this kind of approach can achieve a direct estimation of
dissociation constants. However in the present case, it may not be straightforward
to define bound and unbound states for an IDP.49
The different simulations performed on c-Myc402-412 did not allow the iden-
tification of a dominant binding mode with 10058-F4. Actually, 10058-F4 seems
to interact with the peptide through a multitude of weak interactions with struc-
turally diverse conformations. Those results are consistent with a recent study
using mass spectroscopy suggesting that 10058-F4 may be not able to interact
as strongly as it was described initially in the literature.50 Indeed, the current
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small molecule inhibitor of c-Myc402-412 was reported to stabilize a broad range
of conformations incompatible with dimerization with its partner Max, rather
than order the peptide in a well-defined inactive form. Several other structurally
different molecules were found to disrupt the c-Myc/Max complex, supporting
the hypothesis that the large flexibility of IDPs promotes binding of diverse small
molecules with distinct target conformations through weak interactions.51 This
observation is supported by other IDPs such as as CFTR/NBD1 or the cytoplas-
mic domain of the T-cell receptor ε chain/SIV nef protein complex that are known
to remain partially disordered when in complex with a partner.52, 53 According
to the results presented, the molecular recognition of c-Myc402-412 with 10058-F4
seems to fit both the conformational selection and induced fit models. Even if the
most frequently observed holo conformations are visible, with a lower probability,
in the apo equilibrium ensemble, a few side chain rearrangements are necessary
to eliminate steric clashes with 10058-F4. This observation is in agreement with
the extended conformational selection model where a conformational selection is
combined with structural adjustments.54
The lack of specific interactions between 10058-F4 and c-Myc353-437 makes
the optimization of this compound difficult. The contact matrix in Figure 3.9 A, as
well as the representative snapshots in Figure 3.10 suggest that 10058-F4 interacts
preferentially with Tyr402. The amino acid sequence of the c-Myc bHLHZip
domain is only composed of a unique Tyrosine. Moreover, as it is shown in Figure
3.12, the most hydrophobic part of the protein is located between the amino acids
401 and 406. This observation could explain the position of the binding site in this
region. Interestingly, such hydrophobic clusters are not found in the bHLHZip
domain of Max which seems to be generally more polar. This could explain why
10058-F4 has been reported to be unable to disrupt the Max/Max homodimer.
However, many of the small molecules inhibitors of the c-Myc/Max identified
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Figure 3.12: Hydrophobicity plot of the sequence of the c-Myc and Max bHLHZip
domains. Black: c-Myc. Red: Max. Regions with a positive score are considered
hydrophobic. The location of the c-Myc segment corresponding to amino acids 401 to
406 has been highlighted in bold. Plots generated using a Kyte-Doolittle hydrophobicity
scale. To detect relatively short sequences of hydrophobic and aromatic sites that may
interact favorably with small organic molecules the scale was modified so that Tyrosine
has a hydrophobicity score equal to Phenylalanine and a window width of 3 was used.
Plots produced using the sequences c-Myc353-437 (84 amino acids) and Max24-102 (78
amino acids).
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from in vitro and cellular assays, including 10058-F4, are also able to disrupt
other related protein-protein complex.51, 55 In a larger study relying on yeast two
hybrid assays performed on 32 protein complexes containing either HLH, HLHZip
or bZip domains, 10058-F4 appeared to inhibit strongly c-Myc/Max, but also to
a lesser extend Myod/E2-2, Mad1/Max, Mxi1/Max and Mad3/Max.11 A notable
feature of 10058-F4 is the presence of a benzylidene rhodamine. Actually, few
other potent inhibitors of c-Myc are sharing this characteristic now known to
frequently produce low-micromolar hits in a broad range of assays and against
diverse targets.56 To illustrate, a new benzylidene-rhodanine compound similar
to 10058-F4 was recently found to bind the bZip region of another transcription
factor δFosB.57 Taken together, all the analysis performed to provide a better
understanding of the c-Myc402-412 /10058-F4 complex have highlighted only weak
interactions consistent with a lack of specificity between the ligand and its target.
Therefore, modifying 10058-F4 in order to enhance binding affinity towards c-
Myc proves very challenging and necessarily involves increasing the number of
specific interactions. Furthermore, simulations did not allow to clearly identify
hidden pockets at the surface of the peptide c-Myc402-412. This provides additional
motivation to develop a novel molecular simulation methodology to detect binding
sites that are not seen in the static picture of a protein structure revealed by
experiments.
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This chapter introduces JEDI, a novel methodology to assess the druggability ‘on
the fly’ during a molecular dynamics simulation
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The development of a new medicine is a long and expensive process subjected
to high attrition rates.1 Over the last decades, around 60% of drug discovery
projects failed to identify viable leads able to modulate adequately the activity of
a protein target.2 Analyses of the sequenced human genome indicate that less
than 50% of disease-involved genes code for druggable proteins.3, 4 A protein
target found to be nondruggable late in the drug discovery process is a significant
waste of time and expense in the pharmaceutical industry. Accordingly, an early
assessment of druggability offers the opportunity to focus efforts on tractable
targets, thereby reducing the rate of failure.5 The concept of druggability is
ambiguous because it has been used in many different fields to describe, in a
different context, the properties of genes, proteins and ligands. In the context of
structure-based drug design, protein druggability is often related to the ability
of a therapeutic target to bind a drug-like small molecule, leaving aside many
important facets of the drug discovery and development process such as selectivity,
toxicology or pharmacokinetics.3 Since druggability is closely linked to the notion
of binding site in this specific context, the terms ‘bindability’ or ‘ligandability’
have also been proposed as alternatives.6, 7 This report focuses on the use of a
computational approach for structure-based evaluation of protein druggability.
4.1 Introduction
The idea of relating binding site energetics to structural descriptors was
explored as early as in 1985 with the Grid program of Goodford, and other
related methods.8–11 As interest in druggability developed in the last fifteen years,
more recent efforts have focused on correlating directly structural descriptors
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to druggability. An early effort was contributed by Hadjuk and coworkers.12
NMR-based fragment screening was used to develop a mathematical model for
druggability measurements whereby structural descriptors were correlated to
NMR hit-rates. The methodology is based on the assumption that a druggable
cavity tends to bind more fragments than a nondruggable pocket. A second
approach, called MAPPOD, was published by Cheng et al. shortly after.13 The
authors proposed a scoring function to assess the maximal affinity between a small
molecule and a binding site based on physicochemical and geometric features.
This study also introduced a new category of proteins that are neither ‘druggable’
or ‘nondruggable’, but are instead ‘difficult’ to target with small molecules. The
suggestion was that this category of proteins should be targeted with highly polar
molecules administrated as pro-drugs. These early contributions have paved the
way for a similar class of computational methods that aim to detect and evaluate
potential binding sites at protein surfaces. The public dataset compiled for
MAPPOD was used to parameterize Dscore, a druggability function coupled with
the pocket detector SiteMap.14, 15 Dscore is a simple linear combination of three
descriptors reflecting the volume, enclosure and hydrophobicity of the binding
site. Schmidtke et al. have recently developed a fast methodology based on a
new publically accessible dataset.16, 17 The approach features a logistic regression
analysis to extract local and global hydrophobic descriptors of a protein pocket.
One of the most recent structure-based approaches published in the field is called
Drugpred.18 Drugpred is based on the largest freely accessible non-redundant
dataset and it appears to be less sensitive to binding site structural modifications
that do not dramatically affect pocket properties.18
The above described methods were designed to assess druggability of a
crystallographic protein structure. However, it is well known that sometimes a
few local structural rearrangements around a protein binding site can profoundly
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influence the affinity of a small molecule to its target.19, 20 Accordingly, a second
class of druggability prediction algorithms based on molecular dynamics (MD)
simulations have been proposed.21–23 One of the first methods based on classical
molecular simulations was published by Seco and coworkers.21 In this grid-
based approach, an explicit restrained MD simulation of a protein is performed
in the presence of a given concentration of isopropyl alcohol. The binding
propensities of the probe at the protein surface are then back-computed to
perform binding free energy calculations. A similar protocol was recently applied
on different systems using several kinds of probes without any restraints on the
protein.23 The authors showed that probe molecules could induce both local and
global structural rearrangements of the protein, leading to increases in target
druggability. Nevertheless a frequent concern with these techniques is that the
observed conformational changes reflect denaturation of the protein due to high
probe concentrations. Thus judicious use of positional restraints is required to
limit the occurrence of undesirable conformational changes. Also, probe diffusion
necessary to compute binding propensities in buried cavities can be very slow
with standard MD approaches. To overcome the limitations of current MD
based druggability prediction methods, this report introduces the JEDI algorithm
(‘Just Exploring Druggability at protein Interfaces’). JEDI has been designed
to evaluate protein druggability "on-the-fly" during MD simulations without any
organic probes or protein restraints. The druggability function relies on a set of
geometric parameters describing the volume, the enclosure and the hydrophobicity
of a binding site. The JEDI scoring function is fast, continuous and differentiable.
Accordingly, it can be used as a collective variable to bias MD simulations
and enhance sampling of protein conformations. JEDI has been implemented
in the software PLUMED 1.3 to enable metadynamics simulations and free-
energy calculations with the most popular MD engines.24 The methodology was
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parameterized using the freely accessible Druggable Cavity Directory (DCD)
dataset.17 The sensitivity of the method to binding site conformational changes
was tested with a compiled dataset of cryptic binding sites.
4.2 Materials & Methods
4.2.1 Overview of the JEDI approach
JEDI is a grid-based approach. The methodology includes three major steps
(Figure 4.1A). First, a region of interest where the druggability evaluation will be
conducted must be defined. This area can be located anywhere in the protein
structure in principle, but in this report, efforts are focused on evaluating the
druggability of known binding sites. Thus spatial regions to analyze were defined
from the position of known ligands. A large 3D cubic grid with 1.5 Å spacing
between grid points is initially positioned around the region of interest. Next, only
grid points within 6 Å of one ligand atom were retained. All protein heavy atoms
within 3 Å of a grid point are then selected for druggability calculations and this
set of atoms is referred as the ’binding site region’. This setup is then followed by
either a single point calculation or MD simulations with druggability evaluated at
regular intervals in unbiased simulations, or at each time-step for MD simulations
biased with the JEDI potential. Every druggability assessment requires that the
‘activity’ of all grid points is evaluated, with grid points classified as inactive,
partially active or fully active according to their geometric position in the binding
134 4. JEDI scoring function
site. Then, volume and hydrophobicity descriptors that depend on grid point
activities and local geometric arrangements of protein atoms are computed in
order produce a protein conformation dependent druggability score.
To avoid errors in the druggability predictions due to diffusion of the protein
over the course of an MD simulation, the Cartesian coordinates of the grid points
are re-evaluated prior to each druggability assessment. Firstly, the distance
vector between the center of mass of the protein atoms in the binding site region
in the conformation at the n-th step of the MD simulation (rcom,t=n) and the
initial protein conformation (rcom,t=0) is evaluated. Then, the rotation matrix
that best fits the protein backbone atoms of the binding site region onto their
coordinates at t = 0 is computed using the Wolfgang Kabsch algorithm.25 Finally,
the resulting translation vector and rotation matrix are used to transform the
grid point Cartesian coordinates at t = 0 into grid point Cartesian coordinates at
t = n.
4.2.2 Datasets
Protein structures were taken from the Non Redundant Druggability Dataset
(NRDD) in the DCD compiled by Schmidtke et al.17 A set of 63 unique proteins
has been used to parameterize the JEDI scoring function (Table 4.1 ). Each
protein has been assigned by the authors of the original study an experimental
druggability value from 1 to 10 (from less druggable to more druggable) according
to its capability to bind a drug-like compound. The dataset can be further divided
into three categories: non-druggable (DCDscore 1 to 4), difficult (DCDscore 5
to 7) and druggable (DCDscore 8 to 10). In order to benchmark JEDI against
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Figure 4.1: Overview of the JEDI protocol. A) The region of space for druggability
assessment is determined and all atom models of the protein (and ligand if present) are
prepared as for a conventional MD simulation (1). A grid with a 1.5 Å spacing is placed
around the region of interest (2). A druggability assessment is performed either for
the input structure only, or repeatedly over the course of an MD simulation(3). B) For
every druggability evaluation, all grid points are assigned an initial activity according to
their distance to the ligand in the input structure. Next, grid points overlapping with
protein atoms in the binding site region are inactivated fully or partially. Finally, solvent
exposed grid points are inactivated fully or partially. C) Graphical representation of the
switching functions Sonv (blue) and Soffv (red) for k = 1.0 and ∆ = 1.0.
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an existing methodology, druggability calculations were performed on the energy-
minimized structures of the training dataset using the program fpocket.16, 17 A
detailed list of the dataset is given in Table 4.1, including druggability scores
obtained with both approaches. A validation dataset, called the hidden pocket
dataset, has also been compiled. Each protein in this dataset has two different
structures that exhibit conformational variability in the binding site region that
correlates with variations in the binding affinities of known ligands.
PDB code DCDscore fpocketscore JEDIscore
1BMD 1 0.144 5.06
1BMQ 1 0.016 3.53
1CEN 1 0.087 4.75
1GYM 1 0.069 1.08
1I9Z 1 0.027 0.74
2F7F 1 0.097 2.29
2F94 1 0.585 2.94
2VZS 1 0.064 3.23
1NLJ 2 0.014 5.50
1DUD 3 0.602 4.96
1NNY 3 0.032 4.02
1G1F 3 0.250 4.26
1JF7 3 0.482 4.02
1ONZ 3 0.058 3.00
1AAX 3 0.600 3.93
1Q1M 3 0.300 4.60
2GSS 3 0.731 4.40
2COI 3 0.113 4.71
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1VQ1 4 0.684 6.73
6PAH 4 0.802 5.97
1AJ6 6 0.238 5.50
1FCM 6 0.008 1.94
1HW9 6 0.185 3.92
1JRP 6 0.498 6.53
1KIJ 6 0.119 6.65
1PBF 6 0.033 5.26
1QZR 6 0.257 5.77
1R55 6 0.083 2.51
1T48 6 0.489 7.46
2PK4 6 0.419 6.39
2RMC 6 0.564 6.66
1EVE 7 0.751 6.38
1EZQ 7 0.206 5.26
1KI2 7 0.409 6.75
1E9X 7 0.819 8.29
1TBF 7 0.671 7.32
1W22 7 0.516 3.06
1C14 8 0.831 8.07
1TH6 8 0.706 4.22
1DYR 8 0.758 6.78
1E1X 8 0.729 7.18
I1EP 8 0.804 9.20
1PXX 8 0.885 8.33
1TBB 8 0.307 6.55
1U72 8 0.757 6.33
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2BL9 8 0.809 5.61
3D4S 8 0.693 7.07
1DTL 9 0.822 10.4
1ZGY 9 0.809 9.93
1FK9 9 0.843 9.71
1HSH 9 0.603 8.74
1IHI 9 0.899 7.30
1KV1 9 0.753 7.78
1PWL 9 0.852 8.63
2H79 9 0.757 8.83
3D1X 9 0.735 8.11
1A28 10 0.955 8.77
1ERR 10 0.901 9.34
1LHU 10 0.811 7.57
1NHZ 10 0.963 8.68
2OAX 10 0.943 10.09
2Q7J 10 0.940 8.94
3CAJ 10 0.542 6.64
Table 4.1: Details of the dataset used for the parameterization of JEDI.
4.2.3 JEDI scoring function
The JEDI druggability score is calculated as a linear combination of two
partial-least squared derived descriptors reflecting the volume, and the hydropho-
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bicity (Equation 4.1).
JEDIscore = Vdruglike (αVa + βHa + γ) (4.1)
where Vdruglike, Va and Ha represent respectively the drug-like volume descriptor,
the pocket volume descriptor and the pocket hydrophobicity. α, β and γ are
constants of the model derived by multiple linear regressions against a training
set. All the descriptors presented below are based on cubic spline functions such
that the JEDI potential is continuous and twice differentiable. Two forms of
cubic spline functions have been used operating on variables v and k (Figure 4.1
C). The first one turns ‘off’ with v starting at k at vmin, reaching 0 at vmin + ∆
(Equation 4.2).
Soffv (k, vmin,∆) =

k if m < 0
k
[
(1−m2)2 (1 + 2m2)
]
if 0 ≤ m ≤ 1
0 if m > 1
(4.2)
where m = v−vmin∆ . The second form turns ‘on’ the variable S from 0 to k along
an interval ∆ (Equtation 4.3).
Sonv (k, vmin,∆) =

0 if m < 0
k
[
1− (1−m2)2 (1 + 2m2)
]
if 0 ≤ m ≤ 1
k if m > 1
(4.3)
The active volume descriptor V of the binding site is given by Equation
4.4:





where N is total number of grid points, Vg is the volume of space covered by a
grid point. To capture the shape of the pocket, each grid point is assigned an
activity score ai between 0 and 1 (inactive to active), according to its geometric
position inside the binding pocket (Equation 4.5).
ai = SoffBSi (1.0, BSi,∆BS)S
on
mindi
(1.0, CCmind,∆CC)Sonexposurei (1.0, Emin,∆E)
(4.5)
The first term of Equation 4.5 gradually turns off grid points according their
distances from the region of interest. This term is optional, but is useful to
ensure that fluctuations in druggability scores are not unduly influenced by
conformational changes that are remote from the protein region of interest. The
minimum distance BSi between a grid point i and the M atomic coordinates










With θ = 50.0 Åand rij = rgi− rpj , where rgi and rpj are respectively the position
vectors of grid point i and protein atom j belonging to the binding site region.
The second term in Equation 4.5 causes grid points that overlap with protein
atoms to be gradually inactivated (Figure 4.1B). The minimum distance mindi
between grid points and protein atoms is calculated with an equation similar
to Equation 5.16. The third term in Equation 4.5 gradually inactivates solvent
4.2. Materials & Methods 141









where CC2min/∆CC2 control the distance below which a grid point is considered
as interacting with the protein. GP1min/∆GP1 and GP2min/∆GP2 are used to
select grid points at a given distance interval from the grid point i in order to
penalize solvent exposed grid points. With the default values presented in Table
4.2, a maximum of 44 grid points can be selected around a given grid point i and
the maximum value of exposurei is 23.97 with the present parameterization.
Symbol Definition Value
Vdruglike drug-like volume descriptor 0 to 1
Va pocket volume descriptor [0,∞]
Ha pocket hydrophobicity descriptor 0 to 1
V active volume [0,∞]
ai activity of the grid point i 0 to 1
Hi hydrophobicity of the grid point i 0 to 1
Mapolar number of C and S atoms to calculate JEDIscore [0,∞]
apolar number of C and S atoms surrounding the grid point i [0,∞]
Mpolar number of O and N atoms to calculate JEDIscore [0,∞]
polar number of O and N atoms surrounding the grid point i [0,∞]
Table 4.2: List of variables used to compute JEDIscore.






where Vmax is the maximum active volume descriptor. This constant was set to
be equal to the maximum active volume V calculated for protein binding sites in
the ‘druggable’ category of the DCD dataset. Accordingly, a cavity presenting
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the characteristics of a typical small-molecule binding site will have a typical Va
value in the interval [0.0, 1.0]. In order to penalize overly large or overly small
cavities that are not suitable for drug-like small molecules, the descriptor Vdruglike
is also computed with Equation 4.9.
Vdruglike = SoffV (1.0, Vmax,∆Vmax)SonV (1.0, Vmin,∆Vmin) (4.9)
where Vmin is equal to 0 Å
3 by default. Analysis of pockets from the DCD dataset
suggested a ∆Vmin value of 36 Å
3. For simplicity, the same value was used for
∆max. The effect is that cavities that differ substantially in active volume from
those present in the training set will have a low value of Vdruglike. In turn this will
assign a low JEDIscore to cavities that differ markedly from the training set.
The active grid hydrophobicity function captures the average hydrophobicity












where apolari and polari are respectively the number of apolar (carbon and sulfur)
and polar (oxygen and nitrogen) protein atoms within the distance rhydro defined




Soff‖rij‖ (ai, rhydro,∆rhydro) (4.12)




Soff‖rij‖ (ai, rhydro,∆rhydro) (4.13)
4.2.4 JEDI optimization
The parameters of the JEDI model were optimized using the python module
PyEvolve.26 After investigation, only the CCmind, ∆E, ∆CC2 and rhydro variables
presented in the Table 4.4 were selected for optimization using a range of physically
plausible values (Table 4.3).
Symbol Values Units
CCmind 1.6, 1.8, 2.0, 2.2, 2.4, 2.6 Å
∆E 1, 3, 5, 7, 9, 11, 13 -
∆CC2 0.4, 0.6, 0.8, 1.0, 1.2, 1.4, 1.6 Å
rhydro 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0 Å
Table 4.3: Range of values used for JEDI optimization.
An elitist genetic algorithm was then iterated for 50 generations on a population
of 40 individuals. All individuals consisted of a combination of four parameters.
The value of each parameter was randomly selected according to the range of
values presented in Table 4.3. The fitness function was defined to maximize the
r2 of JEDIscore vs DCDscore values after a Partial Least Squares regression. The
convergence of the r2 was manually verified and the corresponding individual was
selected. Uncertainties in the JEDIscore parameters were determined with 100
iterations of bootstrapping using a split of 0.7/0.3 for the training and validation
sets.
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Symbol Definition Value
α PLS derived volume coefficient 5.31
β PLS derived hydrophobicity coefficient 24.29
γ PLS derived constant according to αandβ -13.39
Vg grid resolution 1.5 Å
3
CCmind distance below which a grid point 2.0 Å
is fully in close contact with the protein
∆CC distance interval over which a grid point 0.5 Å
is in partial contact with the protein
Emin minimum number of grid points between a 10
distance of 2.5 Å and 3.5 Å
from a grid point i interacting with the protein
∆E interval over which a grid point is 3
considered as buried in the cavity
BSmin minimum distance between a 2.0 Å
grid point and binding site atoms below
which the maximal activity is fixed to 1
∆BS distance interval over which 6.0 Å
the maximal activity is fixed to 0
θ constant used for minimum 50.0 Å
distance calculation
CC2min minimum distance below which 0.15 Å
a grid point is overlapping the protein
(for enclosure calculation)
∆CC2 distance interval over which 0.14 Å
a grid point is in partial contact with the
protein (for enclosure calculation)
GP1min distance above which a grid point 2.5 Å
is considered for enclosure calculation
∆GP1 distance interval over which a grid point 0.5 Å
is in partial contact with the protein
GP2min distance below which a grid point 3.0 Å
is fully in close contact with the protein
∆GP2 distance interval over which a grid point 0.5 Å
is in partial contact with the protein
rhydro distance below which a grid point is 4.0 Å
fully in close contact with the protein
(for hydrophobicity calculation)
∆rhydro distance interval over which a grid point is 0.5 Å
in partial contact with the protein
(for hydrophobicity calculation)
Vmax volume below which Vdruglike is equal to 1 316 Å
3
∆Vmax volume interval over which Vdruglike goes from 1 to 0 36 Å
3
Vmin volume below which Vdruglike is equal to 0 0.0 Å
3
∆Vmin volume interval over which Vdruglike goes from 0 to 1 36 Å
3
Table 4.4: List of constants used to compute JEDIscore.
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4.3 Results
4.3.1 Choice of descriptors
The druggability score of the JEDI methodology is based on a linear combi-
nation of structural descriptors characterizing the volume and the hydrophobicity
of a cavity. The choice of those collective variables were influenced by the litera-
ture.6, 12, 13, 17, 18, 27 A rule-based method published by Perola et al. suggested five
suitable descriptors: volume, depth, enclosure, percentage of charged residues and
hydrophobicity. These descriptors summarize a general consensus fairly well.28 Af-
ter investigation, only two descriptors, the active volume and the hydrophobicity,
have been retained. An early version of JEDI also included a descriptor capturing
the degree of ‘buriedness’ of the binding site. The buriedness, as described by
Volkamer et al., was captured as the ratio between the number of hull grid points
in contact with the protein surface and the total number of hull grid points.27
After preliminary investigations, this descriptor was not found to contribute
significantly to the druggability prediction. This is likely because the current
definition of the active volume descriptor is penalizing solvent-exposed grid points
and thus already accounts for buriedness. Consequently, shallow solvent exposed
cavities have a lower active volume descriptor than buried enclosed closed cavities.
The results depicted in Figure 4.2 demonstrate that higher JEDIscore values do
correlate with a larger binding site active volume V and a larger hydrophobicity
descriptor Ha.
Since the publication of the first large scale classification of protein binding































Figure 4.2: Boxplots of values of the (A) active volume V and (B) hydrophobicity
descriptor Ha for the nondruggable, difficult and druggable systems of the training
set. The box is defined using the first and the third quartile while the bar indicates
the median. The edges of the boxplot represent the minimum and the maximum value
observed for each category.
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sites by An et al,29 numerous studies have been conducted in the field of pocket
detection and analysis to improve understanding of the physicochemical properties
that underlie protein-ligand interactions.6, 17, 18, 27 The average volume of a
druggable binding site was evaluated around 600 Å3,29 with maximum values
around 900-1200 Å3.27, 28 These estimates are in line with those computed with
JEDI; the average volume of a binding site represented by the total number of
active and partially active (ai > 0) grid points was found to be 496 ± 202 Å
3
with a maximum value of 1019 Å3. The results shown in Figure 4.2A depict the
distribution of active volume (V ) values for different categories of protein binding
sites. As the active volume is the sum of the grid point volumes weighted by their
activity, it is in general much smaller than the volume of the binding site. An
average value for the whole dataset is V = 125± 60 Å3.
The JEDI hydrophobicity descriptor shares similarities with the descriptor
used by by Eyrisch et al.30, 31 In accordance with previous literature studies,
druggable binding sites tend to have higher average hydrophobicity values (Ha =
0.72±0.03σ) than non-druggable binding sites (Ha = 0.60±0.04σ). This descriptor
was found to be the most significant contribution to the JEDIscore values with a
weight β almost five times larger than the α volume coefficient (Table 4.2). This
observation is in good agreement with the literature, where the apolar character
of a cavity is usually the most important structural descriptor for druggability
assessment.13, 27
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4.3.2 Druggability scoring of diverse protein structures
The JEDI parameters were first optimized using multiple linear regressions
and the elitist selection variant of the genetic algorithm methodology implemented
in the python module PyEvolve.26 JEDI druggability scores obtained at the end of
the process are shown in Figure 4.3A. For comparison, fpocket was used to calculate
the druggability score of each protein in the training dataset (Figure 4.3B). The
results suggest that JEDI predictions are slightly more accurate than those
obtained using fpocket with a r2 of 0.63±0.11 and 0.52±0.13 respectively. Closer
inspection of Figure 4.3A shows that JEDI discriminates fairly well undruggable
sites from druggable sites, but proteins in the difficult category show a large
scatter in JEDIscore values. Clearly, the precise ‘experimental’ DCD druggability
score to assign to a protein can be debated, and this must be kept in mind when
calibrating computational methods against this dataset. Additional tests were
conducted by positioning the grid on buried or solvent exposed regions of the
protein Malate Dehydrogenase (1BMD), where no apparent pockets were observed.
The resulting JEDIscore values where invariably lower than 1.5.
Detailed structural analyses of accurate and inaccurate druggability predictions
for representatives druggable and non-druggable protein binding sites is useful
to characterize the strengths and weaknesses of the present approach. Four
representative structures were chosen for this purpose (Figure 4.4), and JEDI
descriptor values for these structures are shown in Table 4.5.
Figure 4.4A represents the binding site of a malate dehydrogenase in complex
with the coenzyme NAD (PDB 1BMD). This enzyme has been classified as
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Figure 4.3: The correlation of computed druggability scores with DCD database
druggability scores. A) Results for JEDI scores of the DCD training set. B) Results for
fpocket scores of the DCD training set. Proteins discussed in the text, Figure 4.4 and
Table 4.5 are represented with green crosses.
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Figure 4.4: The relationship between JEDI druggability scores, binding site descriptors
and ligand structures. A) Malate dehydrogenase is a nondruggable target predicted
to have an intermediate druggability score. It is in a complex here with the coenzyme
NAD (PDB 1BMD). B) IP phosphatase is a nondruggable binding site that is predicted
to have a low druggability score. It is here in a complex with inositol(1,4)-bisphosphate
and a calcium ion (PDB 1I9Z). C) Mineralocorticoid receptor is a druggable target that
is predicted to have a high druggability score. It is here in a complex with spironolactone
(PDB 2OAX). D) Carbonic anhydrase II is a druggable target that is predicted to have
a low druggability score. It is here in a complex with ethoxzolamide and a zinc ion
(PDB 3CAJ). The protein surface has been colored according to polar (blue) and apolar
(orange) atoms. The 3D ligand conformations are represented in red licorice. Green
dots symbolize grid points, and grid points with activity values ai > 0 are depicted
with smaller spheres. Calcium and zinc ions are respectively represented as grey and
pink van der Waals spheres. Pictures were prepared using the software VMD.
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with NAD for access to the binding site. The binding affinity of several known
nucleotide inhibitors have been previously determined by enzymatic assays.32 The
best competitive inhibitor is the cyclic nucleotide cAMP, presenting a Ki value
560 nM. If this system is clearly evaluated as nondruggable by fpocket (score
= 0.11), it remains challenging for other methodologies such as the NMR-based
approach developed by Hadjuk and coworkers, which predicts the cavity as having
an intermediate druggability. This is in line with the observed JEDIscore value
for this system (5.1). The relatively high JEDIscore is largely due to the relative
large active volume V of the binding site (157 Å3), which is in the range of
V values typical for druggable sites (Table 4.5, first row). Thus, that malate
dehydrogenase is not considered druggable in practice may be more a reflection
of the difficulty for a drug-like molecule to compete with NAD at a ca. 300
µM expected intracellular concentration in mammalian cells,33 rather than the
occurrence of an unusually polar or shallow binding site.
An example of a correct nondruggable prediction is depicted in Figure 4.4B
for the binding site of Inositol Polyphosphate (IP) phosphatase.34 In addition to a
small active volume due to a poor degree of enclosure, this small pocket presents
a very low hydrophobicity score (Table 4.5, second row). This is mainly because
of a Calcium ion in the binding site.
A correctly predicted druggable cavity is shown in figure 4.4C. This mostly
apolar well-enclosed pocket corresponds to the binding site of the S810L mutant
mineralocorticoid receptor interacting with spironolactone (Table 4.5, third row).35
This inhibitor has shown IC50 values in the range of 1.6− 60 nM in a cell-based
luciferase reporter assay.36
Lastly, Figure 4.4D depicts a druggable binding site that is incorrectly
predicted to be ‘difficult’ to target. In addition to a high polarity caused by the
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presence of a zinc ion buried in the pocket, the binding site of carbonic anhydrase
II is particularly small.37 Most successful carbonic anhydrase inhibitors exploit
direct interactions with the buried Zinc ion. The present version of JEDI does
not account for potentially favorable metal-ligand interactions and this explains
the discrepancy between the JEDIscore and DCDscore values (Table 4.5, fourth
row).
Protein V / Å3 Ha JEDIscore DCDscore
Malate dehydrogenase 157 0.64 5.1 1
IP phosphatase 34 0.57 0.7 1
Mineralocorticoid receptor 236 0.80 9.7 10
Carbonic anhydrase II 85 0.76 6.6 10
Table 4.5: JEDI descriptor values for the structures depicted in figure 4.4
4.3.3 Sensitivity to minor structural variations, and performance
A potential concern at the outset of the project was that JEDIscore values
would be unduly sensitive to minor structural variations that are typically observed
when crystal structures of the same protein are solved and refined independently.
A major motivation for the development of JEDI was to observe variability in
JEDIscore between different structures of the same protein, only when conforma-
tional changes relevant for drug design are observed (e.g. a side-chain flip). This
feature requires a subtle balance, on the one hand the methodology should not be
too sensitive to very minor structural changes, but on the other hand it should be
sufficiently sensitive to capture a fluctuation in druggability if the rearrangement
is significant. The strategy here adopted was to evaluate the sensitivity of the
JEDIscore values for comparable conformations of the same protein interacting
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with different ligands. The structural similarity was quantified by means of RMSD
calculations on the backbone and textCβ atoms of the binding site atoms of each
protein. Selected proteins for which RMSD values of the different structures were
less than 0.5 Å were retained for further analysis. Additionally, visualization of
the binding sites confirmed that there was no noticeable difference in binding site
conformation between the different selected structures. Figure 4.5A shows the
distribution of JEDIscore values obtained by this analysis for a representative
protein taken from the ‘nondruggable’, ‘difficult’ and ‘druggable’ categories of the
DCD dataset. Although small fluctuations in JEDIscore are observed in the case
of the difficult and the druggable binding site, the results suggest nevertheless
a good reproducibility and robustness to insignificant structural changes. By
contrast the fpocket methodology sometimes exhibits substantial variations in
druggability that complicates interpretation of the scores (Figure 4.5B). As an
additional test of sensitivity, the dependence of the JEDIscore values on the initial
placement of the grid was assessed by evaluating the druggability of the same
protein after translations of grid point coordinates by up to ±0.5 Å in the x, y,
and z directions in Cartesian space. The druggability predictions were found
to be quite insensitive to such translations, with fluctuations in the JEDIscore
values in the range of 0.1.
Next the computational cost of the JEDI calculations was assessed. An
important consideration is that the calculations should not slow down too much
molecular dynamics simulations. Benchmarks are shown in Table 4.6. If JEDI is
used to monitor druggability values on the fly during an MD simulation, then it
is not necessary to evaluate druggability at every time-step, as snapshots between
successive times-steps are highly correlated. With druggability evaluation every
1 ps the time incurred is negligible, unless the MD simulation is parallelized
across multiple processors. Likewise, single-point druggability estimates of a
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Figure 4.5: The sensitivity of druggability scores to small structural differences. The
boxplots illustrate the fluctuations of the, (A) JEDI and, (B) fpocket druggability scores
obtained from several highly similar conformations of a binding site for three different
proteins. The DCD druggability score of each protein is given in parenthesis in the
x-axis. The nondruggable, difficult and druggable systems selected for druggability
assessment were respectively the dUTPase (PDB codes 1DUD, 1RN8, 1RNJ, 1SEH,
1SYL, 2HR6, 2HRM), the Kringle 1 domain of human plasminogen (PDB codes 1CEA,
1CEB, 2PK4, 1HPK) and the human sex hormone-binding globulin (PDB codes 1LHN,
1LHU, 1LHV, 1LHW). For the sake of consistency, only protein structures presenting a
binding site identified by fpocket were selected.
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protein structure are far faster than alternative methodologies that take seconds to
minutes.15, 17, 27 The implementation of MD simulation protocols biased with JEDI
requires a druggability calculation at each time-step. In this case the performance
loss is approximately a factor of 1.4 to 2.7, depending on the number of processors
used to speed-up the evaluation of the non-bonded energies. Evidently, further
gains in efficiency could be gained by parallelizing key subroutines in the JEDI
code. The relative efficiency is also influenced by the choice of an implicit solvent
model for this study, which dramatically speeds up the evaluation of non-bonded
energies. Overall, the performance was deemed acceptable, given scope for future
improvements.
System Number MD MD/JEDI MD/JEDI
processors (monitor mode) (bias mode)
1 1.3 1.3 0.9
VHL 2 2.5 2.5 1.1
4 3.1 3.0 1.1
1 0.5 0.5 0.4
hPNMT 2 0.8 0.8 0.5
4 1.6 1.3 0.6
Table 4.6: JEDI performance in ns/day for VHL (2278 atoms) and hPNMT (4057
atoms). The results were obtained using a cut-off of 20 Å for the neighbor list, and
100 ps simulations on an Intel Xeon E3-1270 v3 (3.5GHz) processor.
4.3.4 Application to a hidden pockets dataset
Validation of the methodology was pursued by analysis of a set of six
proteins known to adopt distinct binding site conformations in the presence
of different ligands (Figure 4.6). In each instance, two conformations for each
protein were selected for druggability assessments. Protein structures were aligned
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and a grid defined from the largest ligand was used to compute a JEDIscore
value for both conformations. In all instances the ligand atoms were ignored for
druggability calculations. The results of this analysis are shown in Table 4.7.
Human phenylethanolamine N-methyltransferase (hPNMT) is an enzyme involved
in the synthesis of epinephrine from norepinephrine using the cofactor S-adenosyl-
L-methionine to methylate the primary amine of noradrenaline. Two different
hPNMT inhibitors, 1 and 2, have been reported to inhibit the enzyme with Ki
values of 0.28 µM and 0.063 µM respectively (radiochemical assay).38 It has
been shown that these two ligands bind to different conformations of the hPNMT
binding site (Figure 4.6A). Both compounds engage in significant hydrophobic
interactions, but the larger ligand (2) positions a p-chlorophenyl group in a cavity
that is hidden in the hPNMT/1 complex. Formation of the enlarged cavity in
hPNMT/2 necessitates the rearrangement of the side-chain Lys57, as well as a
small displacement of helix α3. The JEDI calculations were able to capture a
favorable increase in druggability of ca. 0.8 units for the protein conformation
seen in hPNMT/2 in comparison with hPNMT/1. The change in druggability is
due to a favorable increase in both V and Ha (Table 4.7, first row).
The von Hippel-Lindau protein (pVHL) forms a complex with the proteins
CUL2, Elongin B and C, and Rbx1. This complex is involved in the ubiquiti-
nation of the transcription factor hypoxia-inducible factor (HIF-1α), leading to
proteasome-mediated degradation of HIF-1α.39 Small molecules 3 and 4 have
been reported to inhibit interactions between pVHL and HIF-1α with Kd values
of 86.1 µM and 27.7 µM respectively (fluorescence polarization assay).20 The
ligands occupy the same binding site, but a different orientation of Arg107 is
observed, giving rise to a slightly more enlarged cavity in VHL/4 (Figure 4.6B).
This translates into a slightly higher JEDIscorevalue for VHL/4 over VHL/3. This
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Figure 4.6: Conformational variability of the hidden pocket dataset. (A) hPNMT in
complex with 1 or 2, (B) VHL in complex with 3 or 4, (C) PLK-1 in complex with
5 or 6, (D) PSMA in complex with 7 or 8, (E) HIV-1 in complex with 9, (F) IL-2 in
complex with 10. Protein regions that are similar in both conformations are represented
in brown. 3D structures of the ligands are displayed in licorice. Pictures were prepared
using the software VMD.
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this is partially offset by a decrease in Va. This is because the displacement of
Arg107 exposes more grid points to the solvent, and as a consequence, grid points
previously fully active become partially active (Table 4.7, second row).
Ligand Protein PDB code JEDIscore V / Å
3
Ha Vdruglike
1 hPNMT 1HNN 8.4 259 0.72 1.0
2 2G8N 9.2 276 0.74 1.0
3 VHL 3ZTD 8.2 118 0.80 1.0
4 3ZTC 8.5 114 0.82 1.0
5 PLK-1 2OWB 8.9 247 0.74 1.0
6 3DB6 8.1 223 0.72 1.0
7 PSMA 3IWW 0.0 493 0.54 0.0
8 2XEG 4.7 341 0.55 0.8
- HIV-RT 1DLO 8.5 192 0.76 1.0
9 3M8P 9.6 213 0.78 1.0
- IL-2 1M47 7.3 77 0.80 1.0
10 1M48 6.2 78 0.75 1.0
Table 4.7: JEDI descriptor values for the hidden pocket dataset.
Serine/threonine-protein kinase or polo-like kinase 1 (PLK-1) is an enzyme
involved in the regulation of cell division., The PLK-1 inhibitor 5 binds with
an IC50 = 730 nM (fluorescence polarization assay) to the ATP binding site,
and also to a subpocket that has been called the adaptive pocket, whereas the
inhibitor 6 shows an IC50 of 530 nM (kinase enzymatic assay) and binds to the
native purine-pocket of the active site (Figure 4.6C).40, 41 However the larger
active volume observed in the PLK-1/5 bound conformation is mainly due to
active grid points around the methylpiperazine moiety of 5. These grid points
are inactive in the PLK-1/6 complex because they are too solvent exposed. The
adaptive pocket seen in PLK-1/6 is predicted to be less druggable than the native
pocket seen in PLK-1/5 by ca. 0.8 units (Table 4.7, third row).
Prostate specific membrane antigen (PSMA) is a glycoprotein overexpressed
as a homodimer in many forms of prostate cancer. Compound 7 is an example of a
4.3. Results 159
first generation of PSMA inhibitors that bind the very polar binding site of PSMA
with a Ki of 11 nM (fluorescence-based NAALADase assay).42 More recently,
compounds belonging to the class of antibody recruiting small molecules targeting
prostate cancer (ARM-P) have been reported, and compound 8 binds PSMA
with a Ki of 0.02 nM (enzymatic assay).43, 44 A crystallographic structure of the
PSMA/8 complex revealed that 8 binds to an open PSMA conformation that was
not observed in the PSMA/7 complex. The large difference in binding affinities
between 7 and 8 appears to be well reproduced by a large difference in JEDIscore
values (Table 4.7, fourth row). However in this instance the active volume V is
much larger than for a typical small molecule binding site and as a consequence
the druggability score is strongly penalized by Vdruglike. This indicates that the
predictions should be treated with care as the binding site differs substantially
from those present in the training set. Compound 8 is unusual because it is
made of a long flexible linker connecting a moiety positioned in the buried PSMA
active site (Figure 4.6D blue square), and another moiety positioned in the arene
binding site at the protein surface (Figure 4.6D black square). The JEDI analysis
was therefore repeated by splitting the initial grid in two regions in order to
predict the druggability of each pocket independently. A first grid was placed
around the active site while a second was located around the DNP pocket. A low
score was observed for the active site in both instances (JEDIscore = 2.3 and 2.6
respectively), because of a very high polarity caused by several ions buried in the
active site, and the presence of numerous polar and charged amino acids. The
DNP pocket in PSMA/8 does score slightly higher (JEDIscore = 3.1) than the
same region in the PSMA/7 complex (JEDIscore = 2.3) but the score remains
small because the DNP pocket is relatively small. Thus the PSMA binding site is
a good illustration of challenging conditions encountered when performing JEDI
analysis of binding sites for ligand that depart from typical rule-of-five compliant
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small molecules.
HIV-RT is an enzyme playing a crucial role in the replication of the HIV virus.
Several non-nucleoside RT inhibitors (NNRTIs) are already on the market.45–49
Druggability predictions were compared for the NNRTI-binding pocket of the
apo structure of HIV-1 RT and in complex with 9 (Figure 4.6E). This compound
belongs to the second generation of NNRTIs and inhibits wild type HIV-RT with
an IC50 of 2.1 nM (antiviral assay).50, 51 The binding site of the holo system
was found to be one of the most druggable pocket analyzed in this work. It is
noteworthy that the NNRTI cavity is actually partially formed in the apo protein,
and has an active volume of V = 192Å3 The holo structure features an enlarged
binding site and side chains rearrangements that increase the hydrophobicity Ha
(Table 4.7, fifth row).
Interleukin-2 (IL-2) is a cytokine playing a crucial role in the regulation of
white blood cells of the immune system. The small molecule 10 binds to a pocket
only partially present in the apo structure. An additional cavity is present in
the holo complex and it forms by displacement of two residues, Phe42 and Glu62
(Figure 4.6F).52 A similar pocket volume descriptor is observed for both apo and
holo form of IL-2. However this time, a higher druggability score was predicted in
absence of ligand, because the hydrophobicity Ha is lower in the IL-2/10 complex
(Table 4.7, sixth row). This occurred because the motion of Phe42 and Glu62
promotes hydrogen bonding with Glu62 and Lys43, activating grid points close
to polar atoms, thus decreasing hydrophobicity.
Overall, the methodology is clearly able to correlate fluctuations in drugga-
bility score with noteworthy binding site conformational changes that have the
potential to impact structure-based ligand design activities. In five cases out of
six, the conformation with the highest JEDIscore corresponds to the conformation
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that binds the most tightly bound ligand. Careful interpretation of the results
is needed when considering unusual protein-ligand complexes, such as PSMA/8.
Quantitative correlation with binding affinities is not expected since the ligands
differ. Further, druggability is not exclusively linked to binding affinity. PSMA is
an example of a binding site for which ligands with very low Ki values are known
(7 and 8), but the low predicted druggability score is adequate since most of the
binding affinity is achieved by means of strongly polar ligand moieties positioned
in the active site. These in turn translate into inauspicious drug-like properties
such as low cell permeability.42, 44
4.4 Conclusion
A novel approach to assess protein binding site druggability has been
developed. The fast, continuous and twice differentiable JEDI druggability
estimator has been implemented in PLUMED and has been used as a collective
variable in order to compute protein druggability at every integration step of a
MD simulation.24 The methodology is able to distinguish nondruggable, difficult
and druggable pockets (r2 = 0.63), and is relatively insensitive to insignificant
structural rearrangements in a binding site. Some limits in the estimator were
exposed, for instance neglect of potential metal-ligand interactions. This could be
remedied with additional structural descriptors. JEDI was tested additionally on
a dataset of hidden pockets for structurally diverse protein targets. The results
show a good ability for the approach to detect structural modifications that
influence the druggability of a protein binding site. With the present version of
the method, care must be taken when performing this analysis on binding sites
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5
JEDI: derivatives and dynamics
This chapter covers the different results obtained using the JEDI approach during
classical and biased molecular dynamics simulations
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5.1 Introduction
The previous chapter introduced a new collective variable (CV) called
JEDI algorithm (‘Just Exploring Druggability at protein Interfaces’). JEDI
has been designed to evaluate protein druggability ‘on-the-fly’ during molecular
dynamics (MD) simulations without any organic probes or protein restraints. The
druggability function relies on a set of geometric parameters describing the volume,
the enclosure and the hydrophobicity of a binding site. Previously, the ability of
JEDI to predict druggability fluctuations during classical MD simulations has
been discussed.
The main novelty of the approach is that the JEDI scoring function is
fast, continuous and differentiable. Accordingly, it can be used as a CV to
bias MD simulations and enhance sampling of protein conformations. JEDI
has been implemented in the software PLUMED 1.3 to enable metadynamics
simulations and free-energy calculations with the most popular MD engines.1
The methodology was parameterized using the freely accessible Druggable Cavity
Directory (DCD) dataset.2 This chapter aims to evaluate the potential for JEDI
analyses to detect cryptic druggable binding sites in proteins. Two different
systems, VHL and hPNMT, were selected to perform several umbrella sampling
simulations. The first system has a binding site exposed to the solvent while
it is buried for the second. However, both are known to adopt local structural
rearrangements that influence the protein druggability.
5.2. Materials & Methods 171
5.2 Materials & Methods
5.2.1 JEDI derivatives
As described in the previous chapter, the JEDI potential is made of a
combination of two structural descriptors (eq 5.1).
JEDIscore = Vdruglike (αVa + βHa + γ) (5.1)
Because the JEDI potential is based on functions that are continuous and
differentiable, the gradient with respect to the Cartesian coordinates x, y, z of




















are the partial derivatives with respect to the Cartesian
coordinates of protein atom j. The derivative of the JEDI potential with respect
to grid Cartesian coordinates does not need to be calculated as the grid is frozen
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Similar equations can be derived for the two other partial derivatives with respect
to y and z Cartesian coordinates.
In the context of a quadratic function (e.g. umbrella sampling), the JEDI
potential is calculated as follows:
UJEDI = k
(
JEDIscore − JEDI targetscore
)2
(5.4)










All the descriptors presented below are based on cubic splines such that the
JEDI potential is continuous and twice differentiable. Two forms of switching
functions have been used operating on variables v and k. The first one turns off
with v starting at k at vmin, reaching 0 at vmin + ∆ (5.6).
Soffv (k, vmin,∆) =

k if m < 0
k
[
(1−m2)2 (1 + 2m2)
]
if 0 ≤ m ≤ 1
0 if m > 1
(5.6)
where m = v−vmin∆ .
The partial derivatives are:























0 if m < 0
4km
[
(1−m2)2 − (1−m2) (1 + 2m2)
]
if 0 ≤ m ≤ 1









1 if m < 0
(1−m2)2 (1 + 2m2) if 0 ≤ m ≤ 1
0 if m > 1
(5.10)
The second form turns ‘on’ the variable S from 0 to k along an interval ∆
(Equtation 5.11).
Sonv (k, vmin,∆) =

0 if m < 0
k
[
1− (1−m2)2 (1 + 2m2)
]
if 0 ≤ m ≤ 1
k if m > 1
(5.11)
























0 if m < 0
−4km
[
(1−m2)2 − (1−m2) (1 + 2m2)
]
if 0 ≤ m ≤ 1






0 if m < 0
1− (1−m2)2 (1 + 2m2) if 0 ≤ m ≤ 1
1 if m > 1
(5.14)
An illustration of the switching functions and their derivatives is given in Figure
5.1.
5.2.1.2 Grid point activity
At every step of the MD simulation, an activity function assigns a score a
between 0 and 1 to a grid point i such that grid points that are too close or too
far to protein atoms have an activity of 0 (eq 5.15). Switching intervals are used
to gradually activate grid points, so partial activity values are possible.
ai = SoffBSi (1.0, BSi,∆BS)S
on
mindi
(1.0, CCmind,∆CC)Sonexposurei (1.0, Emin,∆E)
(5.15)











Figure 5.1: Representation of the two switching functions and first partial derivatives
with respect to v, k = 1, vmin=0 and ∆=1. Sonv and Soffv are colored in blue and red
respectively. The derivatives of each function with respect to m are represented as
dashed lines.











With θ = 5Å and rij = rgi − rpj, where rgi and rpj are respectively the position
vectors of grid point i and protein atom j belonging to the binding site region.
The second term in equation 5.15 causes grid points that overlap with protein
atoms to be gradually inactivated. The minimum distance mindi between grid
points and protein atoms is calculated with an equation similar to eq 5.16. The
third term in equation 5.15 gradually inactivates solvent exposed grid points.









where CC2min/∆CC2 control the distance below which a grid point is considered
as interacting with the protein. GP1min/∆GP1 and GP2min/∆GP2 are used to
select grid points at a given distance interval from the grid point i in order to
penalize solvent exposed grid points.























Because the first term of the equation 13 does not vary with the atomic coordinate
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Because k is a constant, the partial derivatives with respect to xpj are null. Con-
















































Because grid points coordinates do not change during the simulation,
Son‖rik‖ (1.0, GP1min,∆GP1) and S
off
‖rik‖ (1.0, GP2min,∆GP2) are considered as a
constant. Thus, ∂Ei
∂xpj



















is calculated as described in the equation 5.21.
178 5. JEDI: derivatives and dynamics
5.2.1.3 Volume
The active volume descriptor (V ) is calculated as the sum of the activity
of the N grid points weighted by the volume of space Vg monitored by the grid





This volume is then divided by the maximum active volume descriptor (Vmax)






The partial derivative with respect to x of the previous equation varies according

















The partial derivative of the activity is calculated as described in equation 5.18.
The active volume descriptor V is then converted into an overall switching
factor (Vdruglike) in the interval [0,1], with smaller values assigned to large active
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volumes or small active volumes. The aim is to penalize the apparition of too
large or too small cavities on the grid. The range of ‘ideal’ number of active grid
points Vmax to Vmin has been defined according to both smaller and larger values
in the training dataset such that no penalty applies for drug-like small molecules
sized binding site.
Vdruglike = Soffv (1.0, Vmax,∆Vmax)Sonv (1.0, Vmin,∆Vmin) (5.30)



































The active grid hydrophobicity function aims to capture the average hydrophobicity
of the active grid points calculated as:












where apolari and polari are respectively the number of apolar and polar protein








Soff‖rij‖ (ai, rhydro,∆rhydro) (5.37)



















However, the protein atom j cannot be both polar and apolar. Consequently,
two different kinds of derivatives are calculated according to the polar or apolar
property of the protein atom j.
If the protein atom j is polar, then ∂apolari
∂xpj
= 0
























































5.2.2 Molecular Dynamics Simulations
Proteins, ligands and cofactors were prepared using the python script Protein
Preparation Wizard developed by Schrodinger available in Maestro.3 First, missing
hydrogen atoms were added to the structure to assign the appropriate bond number
and formal charge. Then, proteins were manually verified to avoid incomplete side
chains and steric clashes. Molecular dynamics simulations have been performed
using GROMACS 4.5.5 combined with PLUMED 1.3.1, 4 Simulations were carried
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out in implicit solvent using the Generalized Born model and the Onufriev-
Bashford-Case method to calculate the Born radii with a cutoff 20 Å.5, 6 An
energy minimization was performed using the steepest descent algorithm to reach
the convergence parameter of 300 kJ.mol−1.nm−2 of maximum force change. Then,
production runs of 50 ns were performed using a time step of 2.0 fs. Systems
were maintained at a constant temperature of 310 K using a stochastic Berendsen
thermostat with a coupling constant of 1.0 ps.7 The force field Amber99sb-ILDN
was used for the proteins and the GAFF force field has been used for ligands
and cofactors.8, 9 The GAFF parameters for the ligands and the cofactors were
obtained by using the software acpype, in combination with the antechamber
utility from the AMBER12 software package.10, 11 A new non-charged atom type
was created to represent grid points. To avoid interactions between the protein
atoms and the grid points, the Lennard-Jones parameters σ and ε and the atomic
partial charges were equal to zero. All grid points are frozen in space during
energy minimization and molecular dynamics time-steps.
5.2.3 Umbrella Sampling Simulations
Several umbrella sampling calculations were performed using the following
biasing potential:
V (s(r)) = κ(s(r)− s0)2 (5.43)
where s(r) is the JEDIscore of protein conformation r, κ is the force constant
of the biasing potential, and s0 is a target value for JEDIscore.12 Several biased
MD simulations were performed by varying κ and s0 for different systems. The
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resulting trajectories were clustered to identify the most likely conformations
associated with a given set of (κ, s0) values. In order to identify the most
representative conformations present in a trajectory, the single linkage clustering
approach available in GROMACS was used. Two structures were considered as
neighbor if the RMSD was inferior to 1 Å. RMSD calculations were performed
using the coordinates of heavy atoms constituting the binding site, excluding
atoms that can form symmetry equivalent conformations (e.g. Valine Cγ atoms).
Finally, cluster homogeneity was manually checked.
5.2.4 Docking Calculations
Several representative protein structures were extracted from the trajectories
to perform in silico docking experiments. First, hydrogen atoms from both
receptors and ligands were removed using the software Maestro.3 Then, the
docking was realized using Autodock Vina and the Autodock/Vina plugin for
pymol.13, 14 For each complex, the same grid was used, and twenty scores and
poses were estimated. To be consistent with the simulations, His110 and His115
were only protonated on the epsilon nitrogen.
Several representative protein structures were extracted from the trajectories to
perform docking calculations. The Maestro software was used to prepare input
files for both receptors and ligands.3 For VHL, protonation states of binding
site Histidine residues were chosen to be consistent with those from the MD
simulations (in particular, His110 and His115 were protonated on the ε-nitrogen
atom). Docking calculations were performed with the software Autodock Vina
and the Autodock/Vina plugin for pymol.13, 14 For each complex, the same
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docking grid was used, and up to twenty poses were generated. Different protocols
featuring a fully rigid receptor or allowing side-chain flexibility of selected residues
were used.
5.3 Results
Two different systems from the hidden pocket dataset introduced in chapter
4 have been selected to perform classical MD simulations and umbrella sampling
simulations using JEDI.
5.3.1 VHL
The von Hippel-Lindau protein (pVHL) interacts with CUL2, Elongin
B and C, and Rbx1. This complex is involved in the ubiquitination of the
transcription factor hypoxia-inducible factor (HIF) through pVHL, leading to
proteasome-mediated degradation of HIF. Few small molecules were found to
inhibit interactions between pVHL and HIF such as 1 or 2 with a respective Kd
obtained by fluorescence polarization of 86.1 µM and 27.7 µM.15 Both ligands
interact with the same binding site, however a different orientation of the Arg107
is observed (Figure 5.2). In this solvent exposed cavity example, our approach
was also able to detect a more druggable conformation that shows increased Ha.
However, the difference of druggability is limited by a small decrease of the active
volume. Indeed, the displacement of Arg107 exposes more grid points to the
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Figure 5.2: Illustration of the VHL binding site. The conformational changes inducing
an increase of druggability (according to the literature) are highlighted in green (2) while
the less druggable conformation is represented in red (1). The part of the binding site
that is not involved in the druggability variation is colored brown. Ligand corresponding
to each binding site is represented beside the figure. Pictures were prepared using the
software VMD.
solvent. Consequently, grid points previously fully active become partially active
(Table 5.1, first row).
Ligand Protein PDB code JEDIscore V / Å
3
Ha Vdruglike
1 VHL 3ZTD 8.2 118 0.80 1.0
2 3ZTC 8.5 114 0.82 1.0
3 hPNMT 1HNN 8.4 259 0.72 1.0
4 2G8N 9.2 276 0.74 1.0
Table 5.1: JEDI descriptor values for VHL and hPNMT.
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5.3.1.1 Molecular Dynamics Simulations
Further tests were conducted with MD simulations of VHL. Druggability
values were collected every ps over the course of a 50 ns simulation of apo VHL
or VHL/1. The results are shown in Figure 5.3.
The binding site druggability remained stable throughout the VHL/3 sim-
ulation, with an average JEDIscore of 7.8 ± 0.6 which is consistent with the
expected value from previous analyses (Table 5.1, first row). Clustering analysis
with a RMSD cutoff of 1 Å reveals only one major binding site conformation
(76% of the trajectory), that is depicted in Figure 5.3C (right panel). By contrast,
the apo simulation shows an average druggability score of 5.7±0.8. Numerous
structurally different binding site conformations are sampled. In the present MD
simulations, the apo binding pocket is quickly obstructed by the rearrangement
of Tyr98 and His110 inducing a drop of druggability. Dozens of clusters were
identified and the most populated (JEDIscore ca. 6.3) is present in 67% of the
simulation (Figure 5.3C, left panel). This partially closed conformation is mainly
stabilized by hydrogen bonds between the phenolic OH group of Tyr98 and the
protein backbone. His110 is very flexible throughout the simulation. Surprisingly,
significant side-chain rearrangements that partially block the binding site do not
affect dramatically the JEDIscore values. This occurs here because the shift in
position for Tyr98 has created a new hydrophobic sub-pocket that contributes
favorably to the JEDIscore. However this sub-pocket is now occluded by Tyr98
and disconnected from the rest of the binding site. Further, the rest of the VHL
binding site is still partially present, including the central pyrrolidine binding
pocket. Binding site conformations that correspond to extreme druggability fluctu-
ations seen in the apo simulation are depicted in Figure 5.3D. In general, the apo
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Figure 5.3: Druggability fluctuations during an MD simulations of apo VHL. Instan-
taneous values (thin lines) and 300 ps windowed averages (bold lines) of JEDIscore,
Va and Ha during an MD simulation are represented in black, red and blue respectively
for (A) apo VHL and (B) VHL/1. C) The most representative conformation of apo
VHL (left) and VHL/1 (right). D) Instantaneous conformations indicated by numbers
1 and 2 in panel A. Protein surface were colored according to polar (blue) and apolar
atoms (orange). Protein residues discussed in the text are highlighted in green sticks.
The ligand is represented in red sticks. The ligand (transparent red) was overlap with
the conformations from apo VHL by structural alignment to indicate the position of
the binding site. Pictures were prepared using the software VMD.
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conformations that present high JEDIscore values were found to be structurally
very similar to the VHL/1 conformation.
5.3.1.2 Umbrella Sampling Simulations
Umbrella sampling simulations were performed for apo VHL and VHL/1
using equation 5.43 and by varying force constant values for κ and target JEDIscore
values s0. The results are depicted in Figure 5.4. Apo simulations were biased to
achieve a JEDIscore of 8, in expectation with the values previously observed for
ligand bound complexes (Table 5.1, first row). Figure 5.4A (left panel) indicates
that the target druggability value is rapidly achieved in all instances. As expected
fluctuations from the target value decrease with increased κ values. The trajectory
obtained using κ = 2000 kJ.mol−1.nm−2 was subjected to further clustering. The
most populated clusters (51% of the overall trajectory) are very similar to the
VHL/1 structure, with RMSD values always inferior to 2.0 Å. In the unbiased
MD simulation of apo VHL, only 14% of the computed conformation exhibited an
RMSD to the VHL/1 conformation that was smaller than 2.0 Å. Some clusters
still contain conformations with Tyr98 pointing inside the binding site, but the
occurrence is greatly decreased. His110 was also found to be much less flexible.
It is apparent that the ligand binding site is almost fully formed in the most
populated cluster of the biased apo VHL simulation (Figure 5.4A, right panel).
The umbrella sampling simulations of VHL/1 were performed to encourage
the binding site to adopt more druggable conformations. A reference value s0 = 9
was selected based on the JEDIscore of VHL/2. Figure 5.4B left panel shows that
higher κ values are needed to achieve the desired s0 value. This indicates that
the conformations with high JEDIscore values do not form spontaneously. The
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Figure 5.4: Druggability fluctuations during umbrella sampling simulations of (A) apo
VHL and (B) VHL/1. For clarity, only the running averages are shown for four different
spring constants (red: κ = 500 kJ.mol−1.nm−2, blue: κ = 1000 kJ.mol−1.nm−2, green:
κ = 2000 kJ.mol−1.nm−2, magenta: κ = 5000 kJ.mol−1.nm−2). An illustration of the
most populated cluster from the simulation performed with κ = 2000 kJ.mol−1.nm−2
is depicted beside each graph. All other symbols and representations are as in Figure
5.3.
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increase in JEDIscore values that is achieved correlates largely with the position
of Arg107. This amino acid initially closes the binding site, but with the present
bias, it shifts rapidly to a solvent exposed position, thus causing an enlargement of
the binding site. This motion was rarely observed in unbiased MD simulations.
Next, more significant structural rearrangements were sought by performing
umbrella sampling simulations of apo VHL with s0 = 3.0. Results obtained
with κ = 2000 kJ.mol−1.nm−2 are shown in Figure 5.5. Requesting such a low
target druggability value forces VHL to largely collapse the binding site. Here
the collapse is even more pronounced than observed in the unbiased apo VHL
simulations, with the binding pockets of the isoxazole and pyrrolidine moieties
completely masked. Consequently, the pocket volume descriptor Va decreases,
and the active volume V becomes sufficiently low such that the Vdruglike term
penalizes the JEDIscore values. The hydrophobicity descriptor Ha is stable during
the biased simulation, with an average value slightly lower than observed in the
unbiased apo VHL simulation. The closure of the binding site has totally or
partially inactivated numerous grid points that were previously in a buried cavity,
leaving only a few active grid points at the protein surface and near polar groups.
An illustration of the most populated cluster (73% of the trajectory) is depicted
in Figure 5.5B.
Umbrella sampling simulations of apo VHL were also performed by setting
s0 = 10 and κ = 2000 kJ.mol−1.nm−2 to encourage the exploration of confor-
mations with high druggability. The results are presented in Figure 5.6A. As
observed previously, the simulation is rapidly sampling conformations in the
requested range of JEDIscore. As expected, Va and Ha are almost always higher
than in the previously described simulations. However, larger fluctuations are
observed in both descriptors throughout the biased simulation. An increase in
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Figure 5.5: Druggability fluctuations during a biased simulation of apo VHL with
s0 = 3, κ = 2000 kJ.mol−1.nm−2. A) Instantaneous values and running averages of
JEDIscore, Va and Ha. B) Representative conformation of the most populated cluster
identified in the simulation. All other symbols and representations are as in Figure 5.3.
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hydrophobicity Ha is always offset by a decrease of the active volume descriptor
Va and vice versa. Clustering analysis of the trajectory here reveals at least two
significant distinct clusters (populations 18% and 8% respectively). The second
cluster (Figure 5.6C) corresponds to a low Va / high Ha binding site conformation
that is significantly different from the VHL/1 structure. The pyrrolidine pocket
has collapsed and side-chains rearranged to expose hydrophobic groups to the
surface. The first cluster (Figure 5.6B) corresponds to a conformation comparable
to the VHL/3 holo structure. Additionally, Arg107 has adopted a solvent exposed
position that contributes favorably to the JEDIscore as demonstrated previously
(Table 5.1, second row). A significant difference that was not observed in previous
simulations is the rearrangement of Arg69 in the left-hand side part of the binding
site. This conformational rearrangement leads to a more extended cavity with
high druggability scores. The flexibility of the left hand side pocket, has been
recently discussed in the literature in the context of crystallographic structure
analyses of multiple VHL ligand complexes,15 and Galdeano et al. have suggested
that additional interactions between ligands and this part of the binding site may
facilitate the development of improved VHL ligands.
5.3.1.3 Docking
Several docking experiments were carried out to evaluate the conformational
ensembles computed from the umbrella sampling simulations. Figure 5.7A depicts
results obtained using the computed apo VHL conformation closest to the average
conformation of the most populated cluster taken from an umbrella sampling
simulation with s0 = 10.0 and κ = 2000 kJ.mol−1.nm−2 (Figure 5.7B, top).
Ligand 1 was found to adopt a pose that bears a substantial similarity
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Figure 5.6: Druggability fluctuations in apo VHL umbrella sampling simulation with
s0 = 10 and κ = 2000 kJ.mol−1.nm−2. A) Running averages and instantaneous values
of of JEDIscore, Va and Ha, B) The most representative conformation of the first
(top) and second (bottom) most populated clusters observed during the simulation.
All other symbols and representations are as in Figure 5.3.
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Figure 5.7: Ligand docking in JEDI computed VHL conformations. A) Pose of 1
(green sticks) presenting the lowest RMSD with the ligand in its crystallographic position,
docked in the computed apo VHL conformation closest to the average conformation
of the most populated cluster from an umbrella sampling simulation with s0 = 10.0
and κ = 2000 kJ.mol−1.nm−2. B) Same as A) but a more appropriate receptor
conformation to bind the ligand has been chosen from the most populated cluster C)
Same as A) but docked in the computed apo VHL conformation closest to the average
conformation of the most populated cluster from a classical MD simulation. Results
obtained using Vina. The crystallographic pose is in red sticks. All other symbols and
representations are as in Figure 5.3.
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with the crystallographic position of the ligand (RMSD of 3.6 Å), VINA binding
energy of -5.6 kJ.mol−1). This is however not the top-scored pose which had
a VINA binding energy of -6.2 kJ.mol−1. Qualitatively the discrepancy with
the crystallographic binding mode is mostly due to a shift of the isoxazole
ring of 1 that is involved instead in stacking interactions with Tyr112. Closer
inspection of the computed complex indicates that this binding mode is preferred
because the computed ‘left-hand side’ VHL pocket that would normally host
the isoxazole ring is too shallow. However, fluctuations in pocket depth are
apparent in snapshots that are present in the same cluster, and it is possible
to manually select a snapshot with a left-hand-side pocket that more closely
resembles the crystallographic structure. Repeating docking calculations on this
conformation (Figure 5.7B) yields indeed a well scored pose (VINA binding energy
-6.4 kJ.mol−1) that reproduces fairly well the crystallographic position of the
ligand (RMSD of 2.1 Å) though this is again not the top-scoring pose which
had a VINA binding energy of -7 kJ.mol−1. As a control, the same docking
protocol was also applied to the computed apo VHL conformation closest to the
average conformation of the most populated cluster from an unbiased classical MD
simulation (Figure 5.7C). As expected, the lowest-RMSD pose was significantly
different from the crystallographic binding mode of 1 (RMSD of 5.4 Å), VINA
binding energy -6.1 kJ.mol−1). The docking calculations were repeated allowing
side-chain flexibility of Tyr98, Ile109 but no improvements were observed. This is
likely because significant conformational changes involving both side-chain and
backbone atoms rearrangements are necessary to form the ligand binding site
from the apo protein conformations sampled from the unbiased MD simulation.
Conversely, little improvements was seen in the RMSD of the ligands docked into
the JEDI computed conformations with the aid of a flexible side-chain docking
protocol, presumably because the binding site is already largely formed.
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5.3.2 hPNMT
As described in the previous chapter, the human phenylethanolamine N-
methyltransferase (hPNMT) is an enzyme involved in the synthesis of epinephrine
from norepinephrine using the cofactor S-adenosyl- L-methionine to methylate
the amine of noradrenaline. Two different hPNMT inhibitors, 3 and 4 (Table 5.1),
have been identified with a Ki of 0.28 µM and 0.063 µM respectively obtained by
radiochemical assay.16 It has been shown that these two ligands bind two different
conformations of the hPNMT binding site (Figure 5.8). Both compounds perform
hydrophobic interactions but only the larger ligand (3) shows the ability to make
hydrogen bonds with the side chain of Lys57 creating a new subpocket which
is hidden in the complex with the smaller inhibitor (3). The JEDI predictions
were able to capture a favorable increase in druggability due to a rise of the
hydrophobicity and the enlargement of the cavity due the motion of Lys57 at
the edge of the binding site leading to a better druggability (Table 5.1, second
row).
5.3.2.1 Molecular Dynamics Simulations
hPNMT was selected as a case study to explore the JEDI druggability predic-
tions in the context of buried cavities. Apo and holo classical MD simulations were
performed following the protocol described in Materials & Methods. Results of
classical MD trajectories are presented in Figure 5.9. As expected, the simulation
achieved in absence of ligand shows much larger JEDIscore fluctuations than the
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Figure 5.8: Illustration of the hPNMT binding site. The conformational changes
inducing an increase of druggability (according to the literature) are highlighted in
green (4) while the less druggable conformation is represented in red (3). The part
of the binding site that is not involved in the druggability variation is colored brown.
Ligand corresponding to each binding site is represented beside the figure. Pictures
were prepared using the software VMD.
simulation of the complex reflecting a destabilization of the holo binding site con-
formation. Surprisingly, the average JEDIscore of the apo simulation (6.67±0.97)
is slightly higher than the JEDIscore of the holo simulation (6.13±0.71). In
addition, those scores are significantly different than the predictions obtained
previously using a short MD simulation with position restraints (Table 5.1, first
row). This observation is mainly due to an active volume more (Va) important
in the apo simulation (0.15±0.041) than in the holo simulation (0.11±0.038). In
contrast with VHL where the JEDIscore variations are caused by the motion of
few amino acids, backbone motions were observed and Lys57 was not found to
be involved in druggability changes. Clustering analysis with a RMSD cutoff
of 1 Å reveals the presence of one major binding site conformation (47% of the
trajectory) in the holo simulation, that is depicted in Figure 5.9C (right panel).
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By contrast, dozens of clusters were observed during the simulation in absence of
3. The most populated of them (18% of the trajectory) is represented in Figure
5.9C (left panel). The loop between the two alpha-helices highlighted in green in
Figure 5.9C (top part) was found to be much more flexible in the apo simulation
creating frequently enlarged cavities. This backbone flexibility is also described
in the less and more druggable conformations observed in the apo simulation
(Figure 5.9C, bottom part). Indeed, even if the protein secondary structure is
stable along the trajectory, the two α-helices of the N-terminal part of the protein
are occasionally occupying the binding site inducing a drop in the JEDIscore.
An increase in JEDI druggability predictions occurred in presence of the ligand
after 38 ns (7.3±0.68) and remains stable for the rest of the simulation. This
change is correlated to the rearrangement of Tyr85 and Tyr40 in the binding
site. First, Tyr85 moves slightly away from the ligand increasing temporally the
active volume descriptor (35 ns) and allowing to Tyr40 to be more involved in
the binding pocket.
5.3.2.2 Umbrella Sampling Simulations
Umbrella sampling simulations were also performed for this system. A first
set of apo simulations were performed encouraging the hPNMT binding site to
adopt conformations with a JEDIscore of 8.5 (according to Table 5.1, second
row). using different κ values (eq. 5.43). Results are presented in Figure 5.10A.
As expected fluctuations from the target value decrease with increased κ values.
Trajectories obtained with a κ value of 2000 kJ.mol−1.nm−2 were selected to
perform clustering analysis. One main cluster containing 51% of the protein
conformations was found for the apo simulation. An illustration of the snapshot
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Figure 5.9: Results of the classical MD simulations for hPNMT. The running averages
of the changes in JEDIscore, active volume descriptor and hydrophobicity descriptor
are respectively represented in black, red and blue for apo (A) and holo simulation (B).
C) The most representative conformations of the apo (top left) and holo trajectory
(top right) are shown in surface. The conformations indicated by numbers in figure
B are depicted in the bottom part of the figure C. Protein surface were colored
according to polar (blue) and apolar atoms (orange). The amino acids responsible for
JEDIscore variations discussed in the text are highlighted in green. 3 is represented in
red. Concerning the apo simulations, the ligand (transparent) was positioned using a
structural alignment with the holo crystallographic structure. Pictures were prepared
using the software VMD.
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closest to the average structure is presented in Figure 5.10A. In contrast with
the classical MD simulation, the alpha-helix in the N-terminal part (left-hand
side) is much less buried leading to the formation of a pocket more suitable
to bind a drug-like compound. The hPNMT/3 umbrella sampling simulations
forcing the system to adopt more druggable conformations revealed a partial
destabilization of the α-helices increasing the active volume of the binding site.
The most representative conformation is depicted in Figure 5.10B.
5.3.2.3 Docking
Several docking experiments were performed to evaluate the conformational
ensembles computed from the umbrella sampling simulations. Results are pre-
sented in Figure 5.11. First, the computed apo hPNMT conformation closest to
the average conformation of the most populated cluster from an umbrella sampling
simulation with s0 = 8.5 and κ = 2000 kJ.mol−1.nm−2 (Figure 5.11A) was used to
dock 3. A pose similar to that observed in the crystallographic (RMSD of 1.7 Å)
structure was identified in the top-scored poses. As a control, the same docking
protocol was also applied to the computed apo hPNMT conformation closest to
the average conformation of the most populated cluster from the classical MD
simulation (Figure 5.11B). By contrast with the previous study achieved on VHL,
the most representative conformation of the non biased trajectory is also able to
bind the ligand as observed in the crystallographic structure.
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Figure 5.10: Results of the umbrella sampling simulations for VHL in absence
(A) and presence (B) of the ligand. For reasons of clarity, only the running aver-
ages are shown for four different spring constants (red: κ = 500 kJ.mol−1.nm−2,
blue: κ = 1000 kJ.mol−1.nm−2, green: κ = 2000 kJ.mol−1.nm−2, magenta:
κ = 5000 kJ.mol−1.nm−2). An illustration of the most populated cluster of the
simulation performed using a force constant of 2000 kJ.mol−1.nm−2 is depicted beside
each graph. Pictures were prepared using the software VMD.
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Figure 5.11: Ligand docking in JEDI computed hPNMT conformations. A) Pose of
3 (green sticks) presenting the lowest RMSD with the ligand in its crystallographic
position, docked in the computed apo hPNMT conformation closest to the average
conformation of the most populated cluster from an umbrella sampling simulation
with s0 = 8.5 and κ = 2000 kJ.mol−1.nm−2. B) Same as A) but docked in the
computed apo hPNMT conformation closest to the average conformation of the most
populated cluster from a classical MD simulation. Results obtained using Vina. The




In this chapter, the ability of JEDI to detect cryptic binding sites during
classical and biased MD simulations has been investigated. The main novelty
of the approach lies in its potential to bias MD simulations with a JEDI force
that will encourage a protein region to adopt conformations that match desired
druggability scores. The results obtained through several umbrella sampling
simulations of VHL indicate that JEDI enables the rapid sampling of ‘holo-like’
protein conformations that are rarely seen in unbiased apo MD simulations. For
structure-based drug design purposes this would be useful to identify tractable
conformations in targets that may be otherwise considered undruggable from
crystallographic analysis. JEDI also enables biased simulations of protein-ligand
complexes. For structure-based drug design purposes, this would be useful to
identify enlarged cavities that could accommodate a larger analog of an existing
ligand. The results obtained for hPNMT are more contrasted and they highlight
limitations of the current implementation of the JEDI approach in the case of
buried cavities. The conformational sampling may have been biased by using the
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This chapter gives an overview of the concepts presented throughout the thesis and
discusses future development of the JEDI approach
208 6. Conclusion
The work presented throughout this thesis aims to propose a new
methodology to strengthen the reliability of computer-aided structure-based
drug design. Computational approaches have become an increasingly important
part of the drug discovery process.1 Besides the cost reduction in terms of
human resources, time and money, the growing number of three-dimensional
(3D) protein structures available in platforms such as the Protein Data Bank
(PDB) is an additional motivation to the development of new bioinformatics and
chemoinformatics tools.
Protein flexibility is essential in many aspect of cellular biochemistry. In
solution, a protein can not be considered as a static entity and may adopt
structurally different conformations of similar low energies. For instance,
intrinsically disordered proteins (IDPs) can adopt a broad range of conformations,
ranging from collapsed to fully extended. The considerable flexibility of IDPs
facilitates interactions with a large number of proteins and explains why IDPs
often play a crucial role in important cellular processes such as signaling or
transcription.2, 3 IDPs are attractive therapeutic targets as they are often
implicated in a broad range of diseases, such as cancers, cardiovascular disease
or neurodegenerative diseases. However, the considerable flexibility of IDPs
presents a challenge for drug discovery approaches.4 The interactions of small
molecules with IDPs challenge our understanding of molecular recognition and
it is important to clarify the mechanisms of IDP-small molecule interaction
before such proteins can be more routinely targeted. In this thesis, interactions
regulating the formation of IDP-small molecule complexes have been reviewed
through three well-studied systems: the oncoprotein c-Myc, Aβ (amyloid
β-peptide) and α-synuclein.5 They have highlighted the difficulty to develop
pharmaceutical compounds able to bind IDPs with high affinity and selectivity.
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The oncoprotein c-Myc was selected to perform further analysis in
order to provide a better understanding of the interactions characterizing
IDP-small molecule complexes. Several classical molecular dynamics (MD) and
metadynamics simulations were performed to study the conformational sampling
of a c-Myc truncated peptide (c-Myc402-412). Results obtained from simulations
performed in absence and presence of a known inhibitor suggest mainly weak
interactions between the ligand and the peptide. Moreover, it has been found that
c-Myc402-412 remains partially disordered upon the binding of the small molecule.
Therefore, many protein conformations were observed making identification of
hidden pockets very difficult. According to the literature a few well defined
pockets were expected. For this reason, simulation techniques were used to
compute the conformational ensemble of c-Myc402-412 in order to characterize
these pockets. However, many protein conformations were observed making
identification of hidden pockets very difficult. Therefore, those results highlight
the difficulty to propose guidelines to help the optimization of ligands binding
IDPs into more potent inhibitors.
In the last decades, a lack of druggability was found to be one the major
causes of failure in the drug discovery process.6, 7 This thesis introduced a new
computational approach aiming to identify hidden pockets at protein surfaces
and characterize their druggability. JEDI was designed to capture binding site
druggability fluctuations during a MD simulation. The main novelty of this
methodology is the possibility to use the JEDI scoring function as a collective
variable to bias MD simulations. Indeed, druggability predictions are computed
using a potential that is fast, continuous and differentiable. In addition to
210 6. Conclusion
the ability to distinguish druggable from nondruggable binding sites, other
characteristics such as the computational cost and the sensitivity were investigated.
The methodology was found to be as accurate as alternative approaches to
discriminate nondruggable from druggable binding sites. In addition, JEDI is
fast enough to perform classical and biased MD simulations within reasonable time.
Simulations performed on a solvent exposed binding site (VHL) have high-
lighted interesting perspectives for structure-based drug design purposes such as
the identification of new druggable binding site conformations or ligand optimiza-
tion. However, the current implementation of JEDI only allows simulations in
implicit solvent that may cause sampling issues as it has been observed with the
second case study (hPNMT). Further work will focus on replacing the GBSA
implicit solvent model with explicit solvent models, and this is expected to im-
prove the accuracy of the computed conformations.8 Clustering of the biased
simulations in VHL has identified in many instances several structurally distinct
conformations that match a given target druggability value. That druggability is
a degenerate collective variable is not unexpected. An exciting direction for this
work is to couple the JEDI calculations with other collective variables to resolve
the distinct hidden conformational states. This will facilitate the evaluation of the
free energy of these hidden conformational states with respect to the native state
conformation. This parameter is likely to be important for practical applications.
Presumably the feasibility of targeting productively with a ligand a putative
hidden binding site hinges on an acceptable stability relative to the native state.9
Another interesting perspective could be to make JEDI grid calculations on entire
protein structures to identify binding sites and assess their druggability. Such
‘blind detections’ may require clustering approaches to characterize grid point
connectivity and identify distinct binding pockets.
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